1
|
Rico M, Santiago-Díaz P, Rivero A, Santana-Casiano JM. Characterization of polyphenols and carbohydrates exuded by Phaeodactylum tricornutum diatom grown under Cu stress. Sci Rep 2024; 14:9367. [PMID: 38654118 DOI: 10.1038/s41598-024-60252-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2023] [Accepted: 04/20/2024] [Indexed: 04/25/2024] Open
Abstract
This study is focused on analysing polyphenols and carbohydrates released by Phaeodactylum tricornutum (P. tricornutum) diatoms cultured in natural seawater enriched with sublethal and lethal Cu doses. Cu concentrations of 0.31, 0.79 and 1.57 µM reduced cell densities by 37, 82 and 91%, respectively, compared to the control. The total sum of all identified polyphenols and total carbohydrates released by cells grown under lethal Cu levels increased up to 18.8 and 107.4 times, respectively, compared to data from a control experiment. Four different in vitro assays were used to estimate the antioxidant activities of the extracellular compounds: 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical inhibition, cupric ion reducing antioxidant capacity (CUPRAC), ferric reducing antioxidant power and Cu complexing ability (CCA). The highest antioxidant activities were observed in the Cu lethal treatments, where the CCA assay exhibited a greater increase (up to 32.2 times higher than that found in the control experiment) to reduce the concentration of free Cu in the medium and its toxicity. The presence of Cu stimulated the release of polyphenols and carbohydrates to the medium as a detoxification mechanism to survive under lethal levels of Cu regulating its speciation.
Collapse
Affiliation(s)
- Milagros Rico
- Departamento de Química , Facultad de Ciencias del Mar, Universidad de Las Palmas de Gran Canaria, Campus de Tafira, 35017, Las Palmas de Gran Canaria, Canary Islands, Spain.
- Instituto de Oceanografía y Cambio Global (IOCAG), Universidad de Las Palmas de Gran Canaria, Unidad Asociada ULPGC-CSIC, Las Palmas de Gran Canaria, Spain.
| | - Paula Santiago-Díaz
- Departamento de Química , Facultad de Ciencias del Mar, Universidad de Las Palmas de Gran Canaria, Campus de Tafira, 35017, Las Palmas de Gran Canaria, Canary Islands, Spain
- Instituto de Oceanografía y Cambio Global (IOCAG), Universidad de Las Palmas de Gran Canaria, Unidad Asociada ULPGC-CSIC, Las Palmas de Gran Canaria, Spain
| | - Argimiro Rivero
- Departamento de Química , Facultad de Ciencias del Mar, Universidad de Las Palmas de Gran Canaria, Campus de Tafira, 35017, Las Palmas de Gran Canaria, Canary Islands, Spain
- Instituto de Oceanografía y Cambio Global (IOCAG), Universidad de Las Palmas de Gran Canaria, Unidad Asociada ULPGC-CSIC, Las Palmas de Gran Canaria, Spain
| | - Juana Magdalena Santana-Casiano
- Departamento de Química , Facultad de Ciencias del Mar, Universidad de Las Palmas de Gran Canaria, Campus de Tafira, 35017, Las Palmas de Gran Canaria, Canary Islands, Spain
- Instituto de Oceanografía y Cambio Global (IOCAG), Universidad de Las Palmas de Gran Canaria, Unidad Asociada ULPGC-CSIC, Las Palmas de Gran Canaria, Spain
| |
Collapse
|
2
|
Pereyra-Rodríguez JJ, Poveda JL, Rivero A, Serra-Baldrich E, Silvestre JF, Armario-Hita JC, Calleja MÁ, Carrascosa JM, Flórez Á, Herranz P, Comellas M, Ortiz de Frutos FJ. Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA). J Eur Acad Dermatol Venereol 2024; 38:e59-e62. [PMID: 37594914 DOI: 10.1111/jdv.19432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Accepted: 08/11/2023] [Indexed: 08/20/2023]
Affiliation(s)
| | - J L Poveda
- Pharmacy Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - A Rivero
- Independent Consultant Agustin Rivero, Madrid, Spain
| | - E Serra-Baldrich
- Dermatology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autónoma, Barcelona, Spain
| | - J F Silvestre
- Dermatology Department, Hospital General Universitario Dr Balmis-ISABIAL-UMH, Alicante, Spain
| | - J C Armario-Hita
- Dermatology Department, Hospital Universitario de Puerto Real, University of Cádiz, Cádiz, Spain
| | - M Á Calleja
- Pharmacy Department, Hospital Universitario Virgen Macarena, Sevilla, Spain
| | - J M Carrascosa
- Dermatology Department, Hospital Universitari Germans Trias i Pujol, Autonomous University of Barcelona, Barcelona, Spain
| | - Á Flórez
- Dermatology Department, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain
| | - P Herranz
- Dermatology Department, Hospital Universitario La Paz, Madrid, Spain
| | - M Comellas
- Outcomes Research Department, Outcomes'10, Castellón de la Plana, Spain
| | | |
Collapse
|
3
|
Masiá M, Padilla S, Estañ G, Portu J, Silva A, Rivero A, González-Cordón A, García-Fraile L, Martínez O, Bernal E, Galera C, Martínez VB, Macias J, Montero M, García-Rosado D, Vivancos-Gallego MJ, Llenas-García J, Torralba M, García JA, Agulló V, Fernández-González M, Gutiérrez F, Martínez E. Correction: Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection. Trials 2023; 24:614. [PMID: 37759269 PMCID: PMC10523741 DOI: 10.1186/s13063-023-07655-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/29/2023] Open
Affiliation(s)
- M Masiá
- Hospital General Universitario de Elche and Universidad Miguel Hernández de Elche, Elche, Spain
| | - S Padilla
- Hospital General Universitario de Elche and Universidad Miguel Hernández de Elche, Elche, Spain
| | - G Estañ
- Hospital General Universitario de Elche, Elche, Spain
| | - J Portu
- Hospital Universitario Araba, Vitoria-Gasteiz, Spain
| | - A Silva
- Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, Spain
| | - A Rivero
- Hospital Universitario Reina Sofía de Córdoba, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) and Universidad de Córdoba, Córdoba, Spain
| | - A González-Cordón
- Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | | | - O Martínez
- Hospital General Universitario Santa Lucía de Cartagena, Murcia, Spain
| | - E Bernal
- Hospital General Universitario Reina Sofía de Murcia, Murcia, Spain
| | - C Galera
- Hospital Virgen de La Arrixaca, Murcia, Spain
| | | | - J Macias
- Hospital Universitario de Valme, Seville, Spain
| | | | - D García-Rosado
- Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
| | - M J Vivancos-Gallego
- Hospital Ramon y Cajal and Ramon y Cajal Health Research Institute (IRYCIS), Madrid, Spain
| | | | - M Torralba
- Hospital Universitario de Guadalajara, Guadalajara, Spain
| | - J A García
- Hospital General Universitario de Elche, Elche, Spain
| | - V Agulló
- Hospital General Universitario de Elche, Elche, Spain
| | | | - F Gutiérrez
- Hospital General Universitario de Elche and Universidad Miguel Hernández de Elche, Elche, Spain.
| | - E Martínez
- Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| |
Collapse
|
4
|
Santiago-Díaz P, Rivero A, Rico M, González González A, González-Dávila M, Santana-Casiano M. Copper toxicity leads to accumulation of free amino acids and polyphenols in Phaeodactylum tricornutum diatoms. Environ Sci Pollut Res Int 2023; 30:51261-51270. [PMID: 36809613 PMCID: PMC10104907 DOI: 10.1007/s11356-023-25939-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/27/2022] [Accepted: 02/10/2023] [Indexed: 04/16/2023]
Abstract
This work is focused on the effect of lethal and sub-lethal copper (Cu) concentrations on the free amino acid and polyphenol production by the marine diatom Phaeodactylum tricornutum (P. tricornutum) after 12, 18, and 21 days of exposure. The concentrations of 10 amino acids (arginine, aspartic acid, glutamic acid, histidine, lysine, methionine, proline, valine, isoleucine, and phenylalanine) and 10 polyphenols (gallic acid, protocatechuic acid, p-coumaric acid, ferulic acid, catechin, vanillic acid, epicatechin syringic acid, rutin, and gentisic acid) were measured by RP-HPLC. Under lethal doses of Cu, free amino acids reached levels significantly higher than those in the control cells (up to 21.9 times higher), where histidine and methionine showed the highest increases (up to 37.4 and 65.8 times higher, respectively). The total phenolic content also increased up to 11.3 and 5.59 times higher compared to the reference cells, showing gallic acid the highest increase (45.8 times greater). The antioxidant activities of cells exposed to Cu were also enhanced with increasing doses of Cu(II). They were evaluated by 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging ability (RSA), cupric ion reducing antioxidant capacity (CUPRAC), and ferric reducing antioxidant power (FRAP) assays. Malonaldehyde (MDA) exhibited the same tendency: cells grown at the highest lethal Cu concentration yielded the highest MDA level. These findings reflect the involvement of amino acids and polyphenols in protective mechanisms to overcome the toxicity of copper in marine microalgae.
Collapse
Affiliation(s)
- Paula Santiago-Díaz
- Departamento de Química, Facultad de Ciencias del Mar, Universidad de Las Palmas de Gran Canaria, Campus de Tafira, 35017, Las Palmas de Gran Canaria, Spain
- Instituto de Oceanografía Y Cambio Global (IOCAG), Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain
| | - Argimiro Rivero
- Departamento de Química, Facultad de Ciencias del Mar, Universidad de Las Palmas de Gran Canaria, Campus de Tafira, 35017, Las Palmas de Gran Canaria, Spain
- Instituto de Oceanografía Y Cambio Global (IOCAG), Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain
| | - Milagros Rico
- Departamento de Química, Facultad de Ciencias del Mar, Universidad de Las Palmas de Gran Canaria, Campus de Tafira, 35017, Las Palmas de Gran Canaria, Spain.
- Instituto de Oceanografía Y Cambio Global (IOCAG), Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
| | - Aridane González González
- Departamento de Química, Facultad de Ciencias del Mar, Universidad de Las Palmas de Gran Canaria, Campus de Tafira, 35017, Las Palmas de Gran Canaria, Spain
- Instituto de Oceanografía Y Cambio Global (IOCAG), Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain
| | - Melchor González-Dávila
- Departamento de Química, Facultad de Ciencias del Mar, Universidad de Las Palmas de Gran Canaria, Campus de Tafira, 35017, Las Palmas de Gran Canaria, Spain
- Instituto de Oceanografía Y Cambio Global (IOCAG), Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain
| | - Magdalena Santana-Casiano
- Departamento de Química, Facultad de Ciencias del Mar, Universidad de Las Palmas de Gran Canaria, Campus de Tafira, 35017, Las Palmas de Gran Canaria, Spain
- Instituto de Oceanografía Y Cambio Global (IOCAG), Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain
| |
Collapse
|
5
|
Anchuelo J, Rivero A, Galdós P, Alonso L, Astudillo R, Navarrete P, Arrojo E, Jimeno J, Albendea J, Pinto F, Fabregat R, De Juan A, Hinojo C, Hernanz F, Merino P, Díaz de Tuesta M, Borniquel F, Mazaira J, Muñoz P, Prada P. Accelerated partial breast irradiation (APBI) in a single 18 Gy fraction with high-dose-rate brachytherapy (HDR). Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01483-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
6
|
Santiago-Díaz P, Rico M, Rivero A, Santana-Casiano M. Bioactive metabolites of microalgae from Canary Islands for functional food and feed uses. Chem Biodivers 2022; 19:e202200230. [PMID: 35970767 DOI: 10.1002/cbdv.202200230] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Accepted: 08/15/2022] [Indexed: 11/08/2022]
Abstract
Three freshwater microalgae ( Spirogyra sp ., Cosmarium sp . , and Cosmarium blytii ) collected from several locations in Gran Canaria have been studied to explore their potential as a novel source of bioactive compounds for biotechnological applications. Soluble carbohydrates were quantified after extraction with 3M HCl at 100ºC, ranging from 35.8 to 43.3%, and with water at room temperature, ranging from 19 to 22.8%. Amino acids glutamic acid, proline and aspartic acid were quantified by RP-HPLC. Glutamic acid was the most abundant, ranging from 12.2 to 3.63 mg g -1 of dry biomass. Cosmarium blytii was the richest sample in amino acids (24.02 mg g -1 of dry weight). In addition, Cosmarium blytii and Spyrogira sp. exhibited higher radical scavenging activity (RSA) against 1,1-diphenyl-2-picrylhydrazyl (DPPH) than that of the synthetic antioxidant butylhydroxytoluene (BHT), commonly used as food additive. These results show a great potential of these microalgae for exploitation in the food, feed and pharmaceutical industries.
Collapse
Affiliation(s)
- Paula Santiago-Díaz
- Universidad de las Palmas de Gran Canaria, chemistry, carretera de Tafira s/n, 35001, Las Palmas De Gran Canaria, SPAIN
| | - Milagros Rico
- University of Las Palmas de Gran Canaria: Universidad de las Palmas de Gran Canaria, Chemistry, carretera de Tafira s/n, 35017, Las Palmas de Gran Canaria, SPAIN
| | - Argimiro Rivero
- Universidad de las Palmas de Gran Canaria, chemistry, carretera de Tafira s/n, 35001, Las Palmas de Gran Canaria, SPAIN
| | - Magdalena Santana-Casiano
- Universidad de las Palmas de Gran Canaria, chemistry, carretera de Tafina s/n, 35017, las palmas de gran canaria, SPAIN
| |
Collapse
|
7
|
Santiago-Díaz P, Rivero A, Rico M, Gómez-Pinchetti JL. Characterization of Novel Selected Microalgae for Antioxidant Activity and Polyphenols, Amino Acids, and Carbohydrates. Mar Drugs 2021; 20:md20010040. [PMID: 35049895 PMCID: PMC8777807 DOI: 10.3390/md20010040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Revised: 12/28/2021] [Accepted: 12/29/2021] [Indexed: 12/17/2022] Open
Abstract
The biochemical composition of three novel selected microalgae strains (Chlorophyta) was evaluated to confirm their potential possibilities as new sustainably produced biomass with nutritional, functional, and/or biomedical properties. Extracts from cultured Pseudopediastrum boryanum, Chloromonas cf. reticulata, and Chloroidium saccharophilum exhibited higher radical scavenging activity of DPPH (1,1-diphenyl-2-picrylhydrazyl) when compared to butylated hydroxytoluene (BHT), but lower than butylated hydroxyanisole (BHA). Total phenolic compounds and amino acids were determined by newly developed RP-HPLC methods. Total phenolic contents, as µg g−1 of dry biomass, reached 27.1 for C. cf. reticulata, 26.4 for P. boryanum, and 55.8 for C. saccharophilum. Percentages of total analysed amino acids were 24.3, 32.1, and 18.5% of dry biomass, respectively, presenting high values for essential amino acids reaching 54.1, 72.6, and 61.2%, respectively. Glutamic acid was the most abundant free amino acid in all microalgae samples, followed by proline and lysine in C. saccharophilum and P. boryanum, and methionine and lysine in C. reticulata. Soluble carbohydrates in aqueous extracts ranged from 39.6 for C. saccharophilum to 49.3% for C. reticulata, increasing values to 45.1 for C. saccharophilum and 52.7% for P. boryanum in acid hydrolysates of dried biomass. Results confirmed the potential possibilities of these microalgae strains.
Collapse
Affiliation(s)
- Paula Santiago-Díaz
- Departamento de Química, Universidad de Las Palmas de Gran Canaria, Campus de Tafira, 35017 Las Palmas de Gran Canaria, Spain; (P.S.-D.); (A.R.)
- Instituto de Oceanografía y Cambio Global (IOCAG), Campus de Taliarte, Universidad de Las Palmas de Gran Canaria, Unidad Asociada ULPGC-CSIC, 35214 Telde, Spain;
| | - Argimiro Rivero
- Departamento de Química, Universidad de Las Palmas de Gran Canaria, Campus de Tafira, 35017 Las Palmas de Gran Canaria, Spain; (P.S.-D.); (A.R.)
- Instituto de Oceanografía y Cambio Global (IOCAG), Campus de Taliarte, Universidad de Las Palmas de Gran Canaria, Unidad Asociada ULPGC-CSIC, 35214 Telde, Spain;
| | - Milagros Rico
- Departamento de Química, Universidad de Las Palmas de Gran Canaria, Campus de Tafira, 35017 Las Palmas de Gran Canaria, Spain; (P.S.-D.); (A.R.)
- Instituto de Oceanografía y Cambio Global (IOCAG), Campus de Taliarte, Universidad de Las Palmas de Gran Canaria, Unidad Asociada ULPGC-CSIC, 35214 Telde, Spain;
- Correspondence: ; Tel.: +34-928-454418
| | - Juan Luis Gómez-Pinchetti
- Instituto de Oceanografía y Cambio Global (IOCAG), Campus de Taliarte, Universidad de Las Palmas de Gran Canaria, Unidad Asociada ULPGC-CSIC, 35214 Telde, Spain;
- Banco Español de Algas (BEA), Universidad de Las Palmas de Gran Canaria, Muelle de Taliarte s/n, 35214 Telde, Spain
| |
Collapse
|
8
|
Masiá M, Padilla S, Estañ G, Portu J, Silva A, Rivero A, González-Cordón A, García-Fraile L, Martínez O, Bernal E, Galera C, Boix Martínez V, Macias J, Montero M, García-Rosado D, Vivancos-Gallego MJ, Llenas-García J, Torralba M, García JA, Agulló V, Fernández-González M, Gutiérrez F, Martínez E. Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection. Trials 2021; 22:851. [PMID: 34838115 PMCID: PMC8626748 DOI: 10.1186/s13063-021-05777-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Accepted: 10/29/2021] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The incidence of non-AIDS defining cancer (NADC) is higher in people living with HIV (PLWH) than in the general population, and it is already one of the leading causes of death in the HIV-infected population. It is estimated that the situation will be aggravated by the progressive aging of PLWH. Early diagnosis through intensive cancer screening may improve the ability for therapeutic interventions and could be critical in reducing mortality, but it might also increase expenditure and harms associated with adverse events. The aim of this study is to evaluate an enhanced screening program for early diagnosis of cancer in PLWH compared to standard practice. The specific objectives are (1) to compare the frequency of cancer diagnosed at an early stage, (2) to analyze safety of the enhanced program: adverse events and unnecessary interventions, (3) to analyze the cost-utility of the program, and (4) to estimate the overall and site-specific incidence of NADC in PLWH. METHODS We will conduct a multicenter, non-blinded, randomized, controlled trial, comparing two parallel arms: conventional vs enhanced screening. Data will be recorded in an electronic data collection notebook. Conventional intervention group will follow the standard of care screening in the participating centers, according to the European AIDS Clinical Society recommendations, and the enhanced intervention group will follow an expanded screening aimed to early detection of lung, liver, anal, cervical, breast, prostate, colorectal, and skin cancer. The trial will be conducted within the framework of the Spanish AIDS Research Network Cohort (CoRIS). DISCUSSION The trial will evaluate the efficacy, safety, and efficiency of an enhanced screening program for the early diagnosis of cancer in HIV patients compared to standard of care practice. The information provided will be relevant since there are currently no studies on expanded cancer screening strategies in patients with HIV, and available data estimating cost effectiveness or cost-utility of such as programs are scarce. An enhanced program for NADC screening in patients with HIV could lead to early diagnosis and improve the prognosis of these patients, with an acceptable rate of unnecessary interventions, but it is critical to demonstrate that the benefits clearly outweigh the harms, before the strategy could be implemented. TRIAL REGISTRATION ClinicalTrials.gov NCT04735445. Registered on 25 June 2019.
Collapse
Affiliation(s)
- M Masiá
- Hospital General Universitario de Elche and Universidad Miguel Hernández de Elche, Elche, Spain
| | - S Padilla
- Hospital General Universitario de Elche and Universidad Miguel Hernández de Elche, Elche, Spain
| | - G Estañ
- Hospital General Universitario de Elche, Elche, Spain
| | - J Portu
- Hospital Universitario Araba, Vitoria-Gasteiz, Spain
| | - A Silva
- Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, Spain
| | - A Rivero
- Hospital Universitario Reina Sofía de Córdoba, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) and Universidad de Córdoba, Córdoba, Spain
| | - A González-Cordón
- Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | | | - O Martínez
- Hospital General Universitario Santa Lucía de Cartagena, Murcia, Spain
| | - E Bernal
- Hospital General Universitario Reina Sofía de Murcia, Murcia, Spain
| | - C Galera
- Hospital Virgen de la Arrixaca, Murcia, Spain
| | | | - J Macias
- Hospital Universitario de Valme, Seville, Spain
| | | | - D García-Rosado
- Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
| | - M J Vivancos-Gallego
- Hospital Ramon y Cajal and Ramon y Cajal Health Research Institute (IRYCIS), Madrid, Spain
| | | | - M Torralba
- Hospital Universitario de Guadalajara, Guadalajara, Spain
| | - J A García
- Hospital General Universitario de Elche, Elche, Spain
| | - V Agulló
- Hospital General Universitario de Elche, Elche, Spain
| | | | - F Gutiérrez
- Hospital General Universitario de Elche and Universidad Miguel Hernández de Elche, Elche, Spain.
| | - E Martínez
- Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| |
Collapse
|
9
|
Podzamczer D, Micán R, Tiraboschi J, Portilla J, Domingo P, Llibre JM, Ribera E, Vivancos MJ, Morano L, Masiá M, Gómez C, Fanjul F, Payeras A, Inciarte A, Estrada V, Rivero A, Castro Á, Bernal E, Vinuesa D, Knobel H, Troya J, Macías J, Montero M, Sanz J, Navarro-Alcaraz A, Caicedo A, Fernández G, Martínez E, Moreno S. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57). Open Forum Infect Dis 2021; 9:ofab595. [PMID: 35237700 PMCID: PMC8883591 DOI: 10.1093/ofid/ofab595] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2021] [Accepted: 11/21/2021] [Indexed: 11/13/2022] Open
Abstract
Background Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is the reference for combination therapy based on protease inhibitors due to its efficacy, tolerability, and convenience. Head-to-head randomized comparisons between D/C/F/TAF and combination therapy based on integrase inhibitors in antiretroviral-naive patients are lacking. Methods Adult (>18 years old) human immunodeficiency virus-infected antiretroviral-naive patients (HLA-B∗5701 negative and hepatitis B virus negative), with viral load (VL) ≥500 c/mL, were centrally randomized to initiate D/C/F/TAF or dolutegravir/abacavir/lamivudine (DTG/3TC/ABC) after stratifying by VL and CD4 count. Clinical and analytical assessments were performed at weeks 0, 4, 12, 24, and 48. The primary endpoint was VL <50 c/mL at week 48 in the intention-to-treat (ITT)-exposed population (US Food and Drug Administration snapshot analysis, 10% noninferiority margin). Results Between September 2018 and 2019, 316 patients were randomized and 306 patients were included in the ITT-exposed analysis (151 D/C/F/TAF and 155 DTG/3TC/ABC). Almost all (94%) participants were male and their median age was 35 years. Forty percent had a baseline VL >100 000 copies/mL, and 13% had <200 CD4 cells/μL. Median weight was 73 kg and median body mass index was 24 kg/m2. At 48 weeks, 79% (D/C/F/TAF) versus 82% (DTG/3TC/ABC) had VL <50 c/mL (difference, −2.4%; 95% confidence interval [CI], −11.3 to 6.6). Eight percent versus four percent experienced virologic failure but no resistance-associated mutations emerged. Four percent versus six percent had drug discontinuation due to adverse events. In the per-protocol analysis, 94% versus 96% of patients had VL <50 c/mL (difference, −2%; 95% CI, −8.1 to 3.5). There were no differences in CD4 cell count or weight changes. Conclusions We could not demonstrate the noninferiority of D/C/F/TAF relative to DTG/ABC/3TC as initial antiretroviral therapy, although both regimens were similarly well tolerated.
Collapse
Affiliation(s)
- D Podzamczer
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - R Micán
- Hospital La Paz, Madrid, Spain
| | - J Tiraboschi
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - J Portilla
- Hospital General Universitario de Alicante, Alicante, Spain
| | - P Domingo
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - J M Llibre
- Hospital Germans Trias i Pujol, Barcelona, Spain
| | - E Ribera
- Hospital Universitario de la Vall d’Hebrón, Barcelona, Spain
| | - M J Vivancos
- Hospital Universitario Ramón y Cajal, Madrid, Universidad de Alcalá, IRYCIS, Madrid, Spain
| | - L Morano
- Hospital Universitario Álvaro Cunqueiro, Vigo, Spain
| | - M Masiá
- Hospital General Universitario de Elche, Elche, Spain
| | - C Gómez
- Hospital Universitario Virgen de la Victoria-IBIMA, Málaga, Spain
| | - F Fanjul
- Hospital Universitario Son Espases, Palma, Spain
| | - A Payeras
- Hospital Universitario Son Llàtzer, Palma, Spain
| | | | - V Estrada
- Hospital Clínico San Carlos-IdiSSC, Madrid, Spain
| | - A Rivero
- Hospital Universitario Reina Sofía, Córdoba, Spain
| | - Á Castro
- Complejo Hospitalario Universitario, A Coruña, Spain
| | - E Bernal
- Hospital Universitario Reina Sofía, Murcia, Spain
| | - D Vinuesa
- Hospital Universitario Clínico San Cecilio, Granada, Spain
| | - H Knobel
- Hospital del Mar, Barcelona, Spain
| | - J Troya
- Hospital Universitario Infanta Leonor, Madrid, Spain
| | - J Macías
- Hospital Universitario Virgen de Valme, Sevilla, Spain
| | - M Montero
- Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - J Sanz
- Hospital Universitario de La Princesa, Madrid, Spain
| | | | - A Caicedo
- RIS Red de Investigación en SIDA, Madrid, Spain
| | - G Fernández
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | | | - S Moreno
- Hospital Universitario Ramón y Cajal, Madrid, Universidad de Alcalá, IRYCIS, Madrid, Spain
| |
Collapse
|
10
|
Rivas‐Delgado A, López C, Nadeu F, Grau M, Rivero A, Bosch J, Alcoceba M, Gustavo T, Luizaga L, Barcena C, Kelleher N, Martin S, Mozas P, Balague O, Frigola G, Magnano L, Baumann T, Villamor N, Muntañola A, Sancho JM, García‐Sancho AM, Gonzalez‐Barca E, Climent F, Campo E, Giné E, López‐Guillermo A, Beà S. TESTICULAR DIFFUSE LARGE B‐CELL LYMPHOMA: CLINICO‐BIOLOGICAL CHARACTERIZATION, EVALUATION OF TREATMENT RESPONSE AND SURVIVAL. Hematol Oncol 2021. [DOI: 10.1002/hon.15_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. Rivas‐Delgado
- Hospital Clínic de Barcelona Hematology and Pathology Departments Barcelona Spain
| | - C. López
- Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS) Molecular pathology of lymphoid neoplasms Barcelona Spain
| | - F. Nadeu
- Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS) Molecular pathology of lymphoid neoplasms Barcelona Spain
| | - M. Grau
- Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS) Molecular pathology of lymphoid neoplasms Barcelona Spain
| | - A. Rivero
- Hospital Clínic de Barcelona Hematology and Pathology Departments Barcelona Spain
| | - J. Bosch
- Hospital de Bellvitge IDIBELL Pathology Department Barcelona Spain
| | - M. Alcoceba
- Hospital Universitario de Salamanca Hematology Department Salamanca Spain
| | - T. Gustavo
- ICO‐IJC‐Hospital Universitari Germans Trias i Pujol Hematology and Pathology Departments Badalona Spain
| | - L. Luizaga
- Hospital Universitari Mutua de Terrassa Hematology and Pathology Departments Terrasa Spain
| | - C. Barcena
- Hospital Universitario 12 de Octubre Hematology and Pathology Departments Madrid Spain
| | - N. Kelleher
- Institut Català d'Oncologia‐Hospital de Palamos Hematology Department Girona Spain
| | - S. Martin
- Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS) Molecular pathology of lymphoid neoplasms Barcelona Spain
| | - P. Mozas
- Hospital Clínic de Barcelona Hematology and Pathology Departments Barcelona Spain
| | - O. Balague
- Hospital Clínic de Barcelona Hematology and Pathology Departments Barcelona Spain
| | - G. Frigola
- Hospital Clínic de Barcelona Hematology and Pathology Departments Barcelona Spain
| | - L. Magnano
- Hospital Clínic de Barcelona Hematology and Pathology Departments Barcelona Spain
| | - T. Baumann
- Hospital Universitario 12 de Octubre Hematology and Pathology Departments Madrid Spain
| | - N. Villamor
- Hospital Clínic de Barcelona Hematology and Pathology Departments Barcelona Spain
| | - A. Muntañola
- Hospital Universitari Mutua de Terrassa Hematology and Pathology Departments Terrasa Spain
| | - J. M. Sancho
- ICO‐IJC‐Hospital Universitari Germans Trias i Pujol Hematology and Pathology Departments Badalona Spain
| | | | - E. Gonzalez‐Barca
- Institut Català d’Oncologia‐Hospital Duran i Reynals IDIBELL Universitat de Barcelona Hematology Department L'Hospitalet de Llobregat Spain
| | - F. Climent
- Hospital de Bellvitge IDIBELL Pathology Department Barcelona Spain
| | - E. Campo
- Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS) Molecular pathology of lymphoid neoplasms Barcelona Spain
| | - E. Giné
- Hospital Clínic de Barcelona Hematology and Pathology Departments Barcelona Spain
| | - A. López‐Guillermo
- Hospital Clínic de Barcelona Hematology and Pathology Departments Barcelona Spain
| | - S. Beà
- Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS) Molecular pathology of lymphoid neoplasms Barcelona Spain
| |
Collapse
|
11
|
Muntañola A, Magnano L, Mercadal S, Huguet M, Bobillo S, Bastos‐Oreiro M, Jiménez‐Ubieto A, Rovira J, Rivero A, Alcoceba M, Mozas P, Luizaga L, Alonso‐Álvarez S, Rivas‐Delgado A, Giné E, Caballero D, Sancho JM, López‐Guillermo A. OUTCOME OF 133 PATIENTS WITH FOLLICULAR LYMPHOMA (FL) PROGRESSING BEFORE 24 MONTHS (POD24) AFTER IMMUNOCHEMOTHERAPY: A GELTAMO STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.27_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A. Muntañola
- Hospital Universitari Mútua Terrassa Hematology Barcelona Spain
| | - L. Magnano
- Hospital Clínic Barcelona Hematology Barcelona Spain
| | - S. Mercadal
- Hospital Duran Reynals ‐ ICO Hospitalet Hematology Barcelona Spain
| | - M. Huguet
- Hospital Germans Trias i Pujol ‐ ICO Badalona Hematology Barcelona Spain
| | - S. Bobillo
- Hospital Vall d'Hebron Hematology Barcelona Spain
| | | | | | - J. Rovira
- Hospital Universitari Joan XXIII ‐ ICO Tarragona Hematology Tarragona Spain
| | - A. Rivero
- Hospital Clínic Barcelona Hematology Barcelona Spain
| | - M. Alcoceba
- Hospital Universitario de Salamanca Molecular Biology Salamanca Spain
| | - P. Mozas
- Hospital Clínic Barcelona Hematology Barcelona Spain
| | - L. Luizaga
- Hospital Universitari Mútua Terrassa, Pathology Barcelona Spain
| | | | | | - E. Giné
- Hospital Clínic Barcelona Hematology Barcelona Spain
| | - D. Caballero
- Complejo Asistencial Universitario de Salamanca /IBSAL Hematology Salamanca Spain
| | - J. M. Sancho
- Hospital Germans Trias i Pujol ‐ ICO Badalona Hematology Barcelona Spain
| | | |
Collapse
|
12
|
Villa M, Buysse M, Berthomieu A, Rivero A. The transmission-blocking effects of antimalarial drugs revisited: fitness costs and sporontocidal effects of artesunate and sulfadoxine-pyrimethamine. Int J Parasitol 2021; 51:279-289. [PMID: 33508331 DOI: 10.1016/j.ijpara.2020.09.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2020] [Revised: 09/22/2020] [Accepted: 09/23/2020] [Indexed: 12/31/2022]
Abstract
Assays used to evaluate the transmission-blocking activity of antimalarial drugs are largely focused on their potential to inhibit or reduce the infectivity of gametocytes, the blood stages of the parasite that are responsible for the onward transmission to the mosquito vector. For this purpose, the drug is administered concomitantly with gametocyte-infected blood, and the results are evaluated as the percentage of reduction in the number of oocysts in the mosquito midgut. We report the results of a series of experiments that explore the transmission-blocking potential of two key antimalarial drugs, artesunate and sulfadoxine-pyrimethamine, when administered to mosquitoes already infected from a previous blood meal. For this purpose, uninfected mosquitoes and mosquitoes carrying a 6 day old Plasmodium relictum infection (early oocyst stages) were allowed to feed either on a drug-treated or an untreated host in a fully factorial experiment. This protocol allowed us to bypass the gametocyte stages and establish whether the drugs have a sporontocidal effect, i.e. whether they are able to arrest the ongoing development of oocysts and sporozoites, as would be the case when a mosquito takes a post-infection treated blood meal. In a separate experiment, we also explored whether a drug-treated blood meal impacted key life history traits of the mosquito relevant for transmission, and if this depended on their infection status. Our results showed that feeding on an artesunate- or sulfadoxine-pyrimethamine-treated hosts has no epidemiologically relevant effects on the fitness of infected or uninfected mosquitoes. In contrast, when infected mosquitoes fed on an sulfadoxine-pyrimethamine-treated host, we observed both a significant increase in the number of oocysts in the midgut, and a drastic decrease in both sporozoite prevalence (-30%) and burden (-80%) compared with the untreated controls. We discuss the potential mechanisms underlying these seemingly contradictory results and contend that, provided the results are translatable to human malaria, the potential epidemiological and evolutionary consequences of the current preventive use of sulfadoxine-pyrimethamine in malaria-endemic countries could be substantial.
Collapse
Affiliation(s)
- M Villa
- MIVEGEC (CNRS - IRD - Université de Montpellier), France.
| | - M Buysse
- MIVEGEC (CNRS - IRD - Université de Montpellier), France
| | - A Berthomieu
- MIVEGEC (CNRS - IRD - Université de Montpellier), France; CREES (Centre d'Écologie et Évolution de la Santé, Montpellier), 911 avenue Agropolis, 34394 Montpellier, France
| | - A Rivero
- MIVEGEC (CNRS - IRD - Université de Montpellier), France; CREES (Centre d'Écologie et Évolution de la Santé, Montpellier), 911 avenue Agropolis, 34394 Montpellier, France
| |
Collapse
|
13
|
Abstract
A pervasive characteristic of parasite infections is their tendency to be overdispersed. Understanding the mechanisms underlying this overdispersed distribution is of key importance as it may impact the transmission dynamics of the pathogen. Although multiple factors ranging from environmental stochasticity to inter-individual heterogeneity may explain parasite overdispersion, parasite infection is also overdispersed in an inbred host population maintained under laboratory conditions, suggesting that other mechanisms are at play. Here, we show that the aggregated distribution of malaria parasites within mosquito vectors is partially explained by a temporal heterogeneity in parasite infectivity triggered by the bites of mosquitoes. Parasite transmission tripled between the mosquito's first and last blood feed in a period of only 3 h. Surprisingly, the increase in transmission is not associated with an increase in parasite investment in production of the transmissible stage. Overall, we highlight that Plasmodium is capable of responding to the bites of mosquitoes to increase its own transmission at a much faster pace than initially thought and that this is partly responsible for overdispersed distribution of infection. We discuss the underlying mechanisms as well as the broader implications of this plastic response for the epidemiology of malaria.
Collapse
Affiliation(s)
- J Isaïa
- Department of Ecology and Evolution, University of Lausanne, CH-1015 Lausanne, Switzerland
| | - A Rivero
- MIVEGEC (UMR CNRS 5290), Montpellier, France.,CREES (Centre de Recherche en Ecologie et Evolution de la Santé), Montpellier, France
| | - O Glaizot
- Department of Ecology and Evolution, University of Lausanne, CH-1015 Lausanne, Switzerland.,Musée Cantonal de Zoologie, Lausanne, Switzerland
| | - P Christe
- Department of Ecology and Evolution, University of Lausanne, CH-1015 Lausanne, Switzerland
| | - R Pigeault
- Department of Ecology and Evolution, University of Lausanne, CH-1015 Lausanne, Switzerland
| |
Collapse
|
14
|
Corma-Gómez A, Macías J, Lacalle-Remigio JR, Téllez F, Morano L, Rivero A, Serrano M, Ríos MJ, Vera-Méndez FJ, Alados JC, Real LM, Palacios R, Santos IDL, Imatz A, Pineda JA. HIV infection is associated with lower risk of hepatocellular carcinoma after sustained virological response to direct-acting antivirals in hepatitis C infected-patients with advanced fibrosis. Clin Infect Dis 2020; 73:e2109-e2116. [PMID: 32766891 DOI: 10.1093/cid/ciaa1111] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND The aim of this study was to assess the impact of HIV infection on the risk of developing hepatocellular carcinoma (HCC) in HCV-infected patients who achieve sustained virological response (SVR) with direct-acting antiviral (DAA). METHODS Multisite prospective cohort study, where HCV-monoinfected patients and HIV/HCV-coinfected individuals were included if they met: 1) SVR with DAA-based combination; 2) Liver stiffness (LS) ≥9.5 kPa previous to treatment; 3) LS measurement at the SVR time-point. The main endpoint was the occurrence of HCC. Propensity score (PS) was calculated to address potential confounders due to unbalanced distribution of baseline characteristics of HIV/HCV-coinfected and HCV-monoinfected patients. RESULTS 1035 HCV-infected patients were included, 667 (64%) coinfected with HIV. After a median (Q1-Q3) follow-up time of 43 (31-49) months, 19 (1.8%) patients developed HCC [11 (3.0%) HCV-monoinfected, 8(1.2%) HIV/HCV-coinfected individuals; p=0.013]. In the multivariable analysis, HIV co-infection was associated with a lower adjusted risk of developing HCC [sHR=0.27, 95% IC (0.08-0.90); p=0.034]. Predictors of HCC emergence were: HCV genotype 3 [sHR=7.9 (2.5-24.9); p<0.001], MELD score at SVR>10 [sHR=1.37 (1.01-1.86); p=0.043] and LS value at SVR [sHR=1.03 (1.01-1.06) for 1 kPa increase; p=0.011]. Using inverse probability weighting method on the PS, HIV-infected patients had a lower risk of HCC [powered HR=0.33 (0.11-0.85)]. CONCLUSIONS Among HCV-infected patients with advanced fibrosis, who achieve SVR with DAA, HIV-coinfection seems to be associated with a lower risk of HCC occurrence. The underlying causes for this finding need to be investigated.
Collapse
Affiliation(s)
- A Corma-Gómez
- Unit of Infectious Diseases and Microbiology. Hospital Universitario de Valme. Seville. Spain
| | - J Macías
- Unit of Infectious Diseases and Microbiology. Hospital Universitario de Valme. Seville. Spain
| | - J R Lacalle-Remigio
- Division of Preventive Medicine and Public Health, Faculty of Medicine, Universidad de Sevilla, Spain
| | - F Téllez
- Unit of Infectious Diseases, Hospital Universitario de Puerto Real, Faculty of Medicine, Cadiz, Spain
| | - L Morano
- Unit of Infectious Pathology, Hospital Universitario Alvaro Cunqueiro, Vigo, Spain
| | - A Rivero
- Unit of Infectious Diseases, Hospital Universitario Reina Sofia, Córdoba, Spain
| | - M Serrano
- UnitofInfectiousDiseases, Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain
| | - M J Ríos
- Unit of Infectious Diseases, Hospital Universitario Virgen Macarena, Sevilla, Spain
| | - F J Vera-Méndez
- Section of Infectious Medicine/Service of Internal Medicine, Hospital General Universitario Santa Lucía, Cartagena, Spain
| | - J C Alados
- Unit of Clinical Microbiology, University Hospital Jerez, Cadiz, Spain
| | - L M Real
- Unit of Immunology, Biochemistry, Molecular Biology and Surgery, Faculty of Medicine, University of Malaga, Spain
| | - R Palacios
- Unit of Infectious Diseases and Microbiology, Hospital Virgen de la Victoria, Málaga, Spain
| | - I De Los Santos
- Unit of Internal Medicine and Infectious Diseases, Hospital La Princesa, Madrid, Spain
| | - A Imatz
- Unit of Infectious Diseases, Hospital Universitario Bellvitge, Barcelona, Spain
| | - J A Pineda
- Unit of Infectious Diseases and Microbiology. Hospital Universitario de Valme. Seville. Spain
| |
Collapse
|
15
|
López de la Iglesia J, Fernández-Villa T, Rivero A, Carvajal A, Bay Simon E, Martínez Martínez M, Argüello H, Puente H, Fernández Vázquez JP. Predictive factors of COVID-19 in patients with negative RT-qPCR. Semergen 2020; 46 Suppl 1:6-11. [PMID: 32651152 PMCID: PMC7309836 DOI: 10.1016/j.semerg.2020.06.010] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2020] [Accepted: 06/17/2020] [Indexed: 01/05/2023]
Abstract
OBJECTIVE To evaluate the factors associated with false negatives in RT-qPCR in patients with mild-moderate symptoms of COVID-19. MATERIALS AND METHODS This was a cross-sectional study that used a random sample of non-hospitalized patients from the primary care management division of the Healthcare Area of Leon (58 RT-qPCR-positive cases and 52 RT-qPCR-negative cases). Information regarding symptoms was collected and all patients were simultaneously tested using two rapid diagnostic tests - RDTs (Combined - cRDT and Differentiated - dRDT). The association between symptoms and SARS-CoV-2 infection was evaluated by non-conditional logistic regression, with estimation of Odds Ratio. RESULTS A total of 110 subjects were studied, 52% of whom were women (mean age: 48.2±11.0 years). There were 42.3% of negative RT-qPCRs that were positive in some RDTs. Fever over 38°C (present in 35.5% of cases) and anosmia (present in 41.8%) were the symptoms most associated with SARS-CoV-2 infection, a relationship that remained statistically significant in patients with negative RT-qPCR and some positive RDT (aOR=6.64; 95%CI=1.33-33.13 and aOR=19.38; 95% CI=3.69-101.89, respectively). CONCLUSIONS RT-qPCR is the technique of choice in the diagnosis of SARS-CoV-2 infection, but it is not exempt from false negatives. Our results show that patients who present mild or moderate symptoms with negative RT-qPCR, but with fever and/or anosmia, should be considered as suspicious cases and should be evaluated with other diagnostic methods.
Collapse
Affiliation(s)
- J López de la Iglesia
- Especialista en Medicina Familiar y Comunitaria, Centro de salud Condesa, León, Spain
| | - T Fernández-Villa
- Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS)/Instituto de Biomedicina (IBIOMED), Universidad de León, León, Spain.
| | - A Rivero
- Dirección de Enfermería, Gerencia de Atención Primaria del Área de Salud de León, Spain
| | - A Carvajal
- Departamento de Sanidad Animal, Universidad de León, León, Spain
| | - E Bay Simon
- Residente de cuarto año de medicina familiar y comunitaria, Centro de Salud San Andrés del Rabanedo, León, Spain
| | | | - H Argüello
- Departamento de Sanidad Animal, Universidad de León, León, Spain
| | - H Puente
- Departamento de Sanidad Animal, Universidad de León, León, Spain
| | | |
Collapse
|
16
|
Garcia-Rodriguez J, Fernandez-Gomez J, Cozar J, Miñana B, Gomez-Veiga F, Rodriguez-Antolin A, Pórtela P, Blanco E, González J, Baena V, Morales P, Villavicencio H, Palou J, Loizaga A, Ciudin A, Mihai D, Martínez Jabaloyas J, Castelló A, Díez N, Romero F, Subirá J, Chávez A, Capapé V, Mata M, Elizalde J, Lobato J, Jiménez J, Pérez Llorca L, Tenza J, Herranz F, Husillos A, López E, Ramírez D, Blaha I, Izquierdo E, Reina L, Passas J, Díez L, Hevia M, Castells M, Concepción Masip T, Plata A, Asuar Aydillo S, Alonso J, Mateos J, Carballido J, Martínez C, Areche J, Rodríguez R, Hevia V, Álvarez S, Requena M, Prieto R, Carazo J, Márquez J, Gómez E, García J, Amón J, Cepeda M, Álvarez L, Rodríguez V, de la Cruz B, Rivero A, Sánchez J, Mainez J, Medina R, Conde M, Castiñeiras J, González Baena A, Sánchez E, Campanario R, Saiz R, Romero E, Morote J, Raventós C, Celma A, Vázquez F, Gómez A, Buendía E, García N. Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry. Actas Urol Esp 2020; 44:156-163. [PMID: 32113829 DOI: 10.1016/j.acuro.2019.06.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2018] [Revised: 03/26/2019] [Accepted: 06/09/2019] [Indexed: 10/24/2022]
Abstract
BACKGROUND The effect of primary androgen deprivation therapy (ADT) in patients with localized prostate cancer (PCa) has not been well documented. The objective of the present study was to analyze the outcome of tumors treated with ADT as primary therapy in the Spanish Prostate Cancer Registry (19.4% of the series). PATIENTS AND METHODS Patients were classified in three groups: 1) with low/intermediate risk clinically localized tumors; 2) with high risk and locally advanced (T3-4) tumors; 3) with metastatic tumors. Time to castration resistance and overall cancer-specific survival were analyzed. In non-metastatic tumors, survivals in patients treated with ADT were compared with data from patients who underwent local treatments from the Spanish Prostate Cancer Registry. RESULTS 703 cases were analyzed. There were significant differences in the time to castration resistance, which was lower in the group of metastatic tumors. During follow-up, there were 179 deaths (25.5%) of which 89 (12.6%) were due to PCa. After 3 years of ADT, only 14.6% of patients in group 1 had died (1% due to PCa), 20.5% in group 2 and 46.8% in group 3 (9.2% and 31.3% due to PCa, respectively). Cancer-specific survival was significantly worse in group 1 using ADT than radical prostatectomy or radiotherapy. In high-risk and locally advanced tumors, ADT also had a lower cancer-specific survival than local treatments. CONCLUSION A longer time until the castration resistance was observed in patients with well- and intermediate-risk localized tumors treated with ADT. Patients with metastatic tumors showed the shortest time to castration resistance.
Collapse
|
17
|
Lathouwers E, Wong EY, Brown K, Baugh B, Ghys A, Jezorwski J, Mohsine EG, Van Landuyt E, Opsomer M, De Meyer S, De Wit S, Florence E, Vandekerckhove L, Vandercam B, Brunetta J, Klein M, Murphy D, Rachlis A, Walmsley S, Ajana F, Cotte L, Girard PM, Katlama C, Molina JM, Poizot-Martin I, Raffi F, Rey D, Reynes J, Teicher E, Yazdanpanah Y, Arastéh K, Bickel M, Bogner J, Esser S, Faetkenheuer G, Jessen H, Kern W, Rockstroh J, Spinner C, Stellbrink HJ, Stoehr A, Antinori A, Castelli F, Chirianni A, De Luca A, Di Biagio A, Galli M, Lazzarin A, Maggiolo F, Maserati R, Mussini C, Garlicki A, Gasiorowski J, Halota W, Horban A, Parczewski M, Piekarska A, Belonosova E, Chernova O, Dushkina N, Kulagin V, Ryamova E, Shuldyakov A, Sizova N, Tsybakova O, Voronin E, Yakovlev A, Antela A, Arribas JR, Berenguer J, Casado J, Estrada V, Galindo MJ, Garcia Del Toro M, Gatell JM, Gorgolas M, Gutierrez F, Gutierrez MDM, Negredo E, Pineda JA, Podzamczer D, Portilla Sogorb J, Rivero A, Rubio R, Viciana P, De Los Santos I, Clarke A, Gazzard BG, Johnson MA, Orkin C, Reeves I, Waters L, Benson P, Bhatti L, Bredeek F, Crofoot G, Cunningham D, DeJesus E, Eron J, Felizarta F, Franco R, Gallant J, Hagins D, Henry K, Jayaweera D, Lucasti C, Martorell C, McDonald C, McGowan J, Mills A, Morales-Ramirez J, Prelutsky D, Ramgopal M, Rashbaum B, Ruane P, Slim J, Wilkin A, deVente J, De Wit S, Florence E, Moutschen M, Van Wijngaerden E, Vandekerckhove L, Vandercam B, Brunetta J, Conway B, Klein M, Murphy D, Rachlis A, Shafran S, Walmsley S, Ajana F, Cotte L, Girard PM, Katlama C, Molina JM, Poizot-Martin I, Raffi F, Rey D, Reynes J, Teicher E, Yazdanpanah Y, Gasiorowski J, Halota W, Horban A, Piekarska A, Witor A, Arribas JR, Perez-Valero I, Berenguer J, Casado J, Gatell JM, Gutierrez F, Galindo MJ, Gutierrez MDM, Iribarren JA, Knobel H, Negredo E, Pineda JA, Podzamczer D, Portilla Sogorb J, Pulido F, Ricart C, Rivero A, Santos Gil I, Blaxhult A, Flamholc L, Gisslèn M, Thalme A, Fehr J, Rauch A, Stoeckle M, Clarke A, Gazzard BG, Johnson MA, Orkin C, Post F, Ustianowski A, Waters L, Bailey J, Benson P, Bhatti L, Brar I, Bredeek UF, Brinson C, Crofoot G, Cunningham D, DeJesus E, Dietz C, Dretler R, Eron J, Felizarta F, Fichtenbaum C, Gallant J, Gathe J, Hagins D, Henn S, Henry KW, Huhn G, Jain M, Lucasti C, Martorell C, McDonald C, Mills A, Morales-Ramirez J, Mounzer K, Nahass R, Olivet H, Osiyemi O, Prelutsky D, Ramgopal M, Rashbaum B, Richmond G, Ruane P, Scarsella A, Scribner A, Shalit P, Shamblaw D, Slim J, Tashima K, Voskuhl G, Ward D, Wilkin A, de Vente J. Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials. AIDS Res Hum Retroviruses 2020; 36:48-57. [PMID: 31516033 PMCID: PMC6944133 DOI: 10.1089/aid.2019.0111] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is being investigated in two Phase III trials, AMBER (NCT02431247; treatment-naive adults) and EMERALD (NCT02269917; treatment-experienced, virologically suppressed adults). Week 48 AMBER and EMERALD resistance analyses are presented. Postbaseline samples for genotyping/phenotyping were analyzed from protocol-defined virologic failures (PDVFs) with viral load (VL) ≥400 copies/mL at failure/later time points. Post hoc analyses were deep sequencing in AMBER, and HIV-1 proviral DNA from baseline samples (VL <50 copies/mL) in EMERALD. Through week 48 across both studies, no darunavir, primary PI, or tenofovir resistance-associated mutations (RAMs) were observed in HIV-1 viruses of 1,125 participants receiving D/C/F/TAF or 629 receiving boosted darunavir plus emtricitabine/tenofovir-disoproxil-fumarate. In AMBER, the nucleos(t)ide analog reverse transcriptase inhibitor (N(t)RTI) RAM M184I/V was identified in HIV-1 of one participant during D/C/F/TAF treatment. M184V was detected pretreatment as a minority variant (9%). In EMERALD, in participants with prior VF and genoarchive data (N = 140; 98 D/C/F/TAF and 42 control), 4% had viruses with darunavir RAMs, 38% with emtricitabine RAMs, mainly at position 184 (41% not fully susceptible to emtricitabine), 4% with tenofovir RAMs, and 21% ≥ 3 thymidine analog-associated mutations (24% not fully susceptible to tenofovir) detected at screening. All achieved VL <50 copies/mL at week 48 or prior discontinuation. D/C/F/TAF has a high genetic barrier to resistance; no darunavir, primary PI, or tenofovir RAMs were observed through 48 weeks in AMBER and EMERALD. Only one postbaseline M184I/V RAM was observed in HIV-1 of an AMBER participant. In EMERALD, baseline archived RAMs to darunavir, emtricitabine, and tenofovir in participants with prior VF did not preclude virologic response.
Collapse
Affiliation(s)
| | - Eric Y Wong
- Janssen Scientific Affairs, LLC, Titusville, New Jersey
| | | | - Bryan Baugh
- Janssen Research & Development LLC, Raritan, New Jersey
| | - Anne Ghys
- Janssen Pharmaceutica NV, Beerse, Belgium
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Eron JJ, Orkin C, Cunningham D, Pulido F, Post FA, De Wit S, Lathouwers E, Hufkens V, Jezorwski J, Petrovic R, Brown K, Van Landuyt E, Opsomer M, De Wit S, Florence E, Moutschen M, Van Wijngaerden E, Vandekerckhove L, Vandercam B, Brunetta J, Conway B, Klein M, Murphy D, Rachlis A, Shafran S, Walmsley S, Ajana F, Cotte L, Girardy PM, Katlama C, Molina JM, Poizot-Martin I, Raffi F, Rey D, Reynes J, Teicher E, Yazdanpanah Y, Gasiorowski J, Halota W, Horban A, Piekarska A, Witor A, Arribas J, Perez-Valero I, Berenguer J, Casado J, Gatell J, Gutierrez F, Galindo M, Gutierrez M, Iribarren J, Knobel H, Negredo E, Pineda J, Podzamczer D, Sogorb J, Pulido F, Ricart C, Rivero A, Santos Gil I, Blaxhult A, Flamholc L, Gisslèn M, Thalme A, Fehr J, Rauch A, Stoeckle M, Clarke A, Gazzard B, Johnson M, Orkin C, Post F, Ustianowski A, Waters L, Bailey J, Benson P, Bhatti L, Brar I, Bredeek U, Brinson C, Crofoot G, Cunningham D, DeJesus E, Dietz C, Dretler R, Eron J, Felizarta F, Fichtenbaum C, Gallant J, Gathe J, Hagins D, Henn S, Henry W, Huhn G, Jain M, Lucasti C, Martorell C, McDonald C, Mills A, Morales-Ramirez J, Mounzer K, Nahass R, Olivet H, Osiyemi O, Prelutsky D, Ramgopal M, Rashbaum B, Richmond G, Ruane P, Scarsella A, Scribner A, Shalit P, Shamblaw D, Slim J, Tashima K, Voskuhl G, Ward D, Wilkin A, de Vente J. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1. Antiviral Res 2019; 170:104543. [DOI: 10.1016/j.antiviral.2019.104543] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2019] [Revised: 06/19/2019] [Accepted: 06/20/2019] [Indexed: 11/27/2022]
|
19
|
Mozas P, Magnano L, Rivas-Delgado A, Rivero A, Nadeu F, Veloza L, González-Farré B, Baumann T, Balagué O, Giné E, Delgado J, Villamor N, Campo E, López-Guillermo A. PATTERNS OF CHANGE IN TREATMENT, SURVIVAL, HISTOLOGICAL TRANSFORMATION, AND SECONDARY MALIGNANCIES OF FOLLICULAR LYMPHOMA OVER THE LAST 4 DECADES: A SINGLE CENTER EXPERIENCE. Hematol Oncol 2019. [DOI: 10.1002/hon.66_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- P. Mozas
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - L. Magnano
- Hematopathology Unit; Pathology Department, Hospital Clínic de Barcelona; Barcelona Spain
| | | | - A. Rivero
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - F. Nadeu
- Lymphoid Malignancies; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Barcelona Spain
| | - L. Veloza
- Pathology; Hospital Clínic de Barcelona; Barcelona Spain
| | | | - T. Baumann
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - O. Balagué
- Pathology; Hospital Clínic de Barcelona; Barcelona Spain
| | - E. Giné
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - J. Delgado
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - N. Villamor
- Hematopathology Unit; Pathology Department, Hospital Clínic de Barcelona; Barcelona Spain
| | - E. Campo
- Pathology; Hospital Clínic de Barcelona; Barcelona Spain
| | | |
Collapse
|
20
|
Rivero‐Juarez A, Tellez F, Castaño‐Carracedo M, Merino D, Espinosa N, Santos J, Macias J, Paniagua‐García M, Zapata‐Lopez A, Collado A, Gómez‐Vidal MA, Perez‐Stachowski J, Muñoz‐Medina L, Fernandez‐Fuertes E, Rivero A. Parenteral drug use as the main barrier to hepatitis C treatment uptake inHIV‐infected patients. HIV Med 2019; 20:359-367. [DOI: 10.1111/hiv.12715] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/17/2018] [Indexed: 12/18/2022]
Affiliation(s)
- A Rivero‐Juarez
- Infectious Diseases Unit Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC) Hospital Universitario Reina Sofía de Córdoba Universidad de Córdoba Córdoba Spain
| | - F Tellez
- Infectious Diseases Unit Hospital Universitario de Puerto Real Instituto de Investigación e Innovación en Ciencias Biomédicas de la Provincia de Cádiz Universidad de Cádiz Cádiz Spain
| | - M Castaño‐Carracedo
- Infectious Diseases Unit Hospital Regional Universitario de Málaga Málaga Spain
| | - D Merino
- Infectious Diseases Unit Hospitales Juan Ramón Jiménez e Infanta Elena de Huelva Huelva Spain
| | - N Espinosa
- Infectious Diseases Unit Hospital Universitario Virgen del Rocio Instituto de Biomedicina de Sevilla (iBiS) Sevilla Spain
| | - J Santos
- Infectious Diseases Unit Hospital Universitario Virgen de la Victoria Complejo Hospitalario Provincial de Málaga Málaga Spain
| | - J Macias
- Infectious Diseases Unit Hospital Universitario de Valme Instituto de Biomedicina de Sevilla (iBiS) Sevilla Spain
| | - M Paniagua‐García
- Infectious Diseases Unit Hospital Universitario Virgen Macarena Instituto de Biomedicina de Sevilla (iBiS) Sevilla Spain
| | | | - A Collado
- Infectious Diseases Unit Complejo Hospitalario Torrecárdenas Almería Spain
| | - MA Gómez‐Vidal
- Infectious Diseases Unit Complejo Hospitalario de Jaén Jaén Spain
| | | | - L Muñoz‐Medina
- Infectious Diseases Unit Hospital Universitario San Cecilio Granada Spain
| | | | - A Rivero
- Infectious Diseases Unit Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC) Hospital Universitario Reina Sofía de Córdoba Universidad de Córdoba Córdoba Spain
| | | |
Collapse
|
21
|
Clemente-Gallardo J, Ferrer A, Íñiguez D, Rivero A, Ruiz G, Tarancón A. Do researchers collaborate in a similar way to publish and to develop projects? J Informetr 2019. [DOI: 10.1016/j.joi.2018.11.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
22
|
Rivero-Juarez A, Aguado R, Lopez-Lopez P, Sanchez-Frias M, Frias M, Briceño J, de la Mata M, Torre-Cisneros J, Rivero A. Prevalence of hepatitis E virus infection in liver donors in Spain. Clin Microbiol Infect 2018; 24:1218-1219. [DOI: 10.1016/j.cmi.2018.06.030] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2018] [Revised: 06/26/2018] [Accepted: 06/28/2018] [Indexed: 01/11/2023]
|
23
|
Rivero-Juarez A, Frias M, Lopez-Lopez P, Martinez-Peinado A, Risalde MÁ, Brieva T, Machuca I, Camacho Á, García-Bocanegra I, Gomez-Villamandos JC, Rivero A. Detection of hepatitis E virus RNA in saliva for diagnosis of acute infection. Zoonoses Public Health 2018; 65:584-588. [PMID: 29659194 DOI: 10.1111/zph.12472] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2017] [Indexed: 12/31/2022]
Abstract
Diagnosis of acute hepatitis E virus (HEV) infection is established by detection of anti-HEV IgM antibodies by ELISA or by amplification of serum viral RNA. Here, we evaluate the diagnostic value of testing HEV RNA in saliva to identify patients with acute HEV infection. Prospective proof-of-concept study including patients with acute hepatitis. Whole blood and neat saliva samples were obtained from all patients. Saliva samples were processed and analysed for HEV RNA by RT-PCR within 2 hr after collection. A total of 34 patients with acute hepatitis and 12 healthy donors were included in the study. HEV RNA in serum was confirmed by RT-PCR in eight of these patients (23.5%; 95% CI: 12.2%-40.2%). HEV was isolated in the saliva of eight of 34 patients (23.5%; 95% CI: 12.2%-40.2%). All patients with HEV RNA amplified in saliva had detectable HEV RNA in serum. HEV was isolated neither in the saliva of any of the 26 patients without detectable HEV RNA in serum nor in healthy donors. Our study suggests that acute HEV infection could be diagnosed by assessing viral load in saliva.
Collapse
Affiliation(s)
- A Rivero-Juarez
- Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía de Córdoba, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain
| | - M Frias
- Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía de Córdoba, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain
| | - P Lopez-Lopez
- Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía de Córdoba, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain
| | - A Martinez-Peinado
- Servicio de Análisis Clínico, Hospital Universitario Reina Sofía de Córdoba, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain
| | - M Á Risalde
- Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía de Córdoba, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain
| | - T Brieva
- Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía de Córdoba, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain
| | - I Machuca
- Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía de Córdoba, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain
| | - Á Camacho
- Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía de Córdoba, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain
| | - I García-Bocanegra
- Animal Health Department, Veterinary Science College, Universidad de Córdoba, Cordoba, Spain
| | - J C Gomez-Villamandos
- Animal Pathology Department, Veterinary Science College, Universidad de Córdoba, Cordoba, Spain
| | - A Rivero
- Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía de Córdoba, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain
| |
Collapse
|
24
|
Carreño-Tarragona G, Cedena T, Montejano L, Alonso R, Miras F, Valeri A, Rivero A, Lahuerta JJ, Martinez-Lopez J. Papain-treated panels are a simple method for the identification of alloantibodies in multiple myeloma patients treated with anti-CD38-based therapies. Transfus Med 2018; 29:193-196. [DOI: 10.1111/tme.12508] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2017] [Revised: 12/18/2017] [Accepted: 12/31/2017] [Indexed: 12/31/2022]
Affiliation(s)
- G. Carreño-Tarragona
- Department of Hematology; Hospital Universitario 12 de Octubre, Universidad Complutense, CNIO; Madrid Spain
| | - T. Cedena
- Department of Hematology; Hospital Universitario 12 de Octubre, Universidad Complutense, CNIO; Madrid Spain
| | - L. Montejano
- Department of Hematology; Hospital Universitario 12 de Octubre, Universidad Complutense, CNIO; Madrid Spain
| | - R. Alonso
- Department of Hematology; Hospital Universitario 12 de Octubre, Universidad Complutense, CNIO; Madrid Spain
| | - F. Miras
- Department of Hematology; Hospital Universitario 12 de Octubre, Universidad Complutense, CNIO; Madrid Spain
| | - A. Valeri
- Department of Hematology; Hospital Universitario 12 de Octubre, Universidad Complutense, CNIO; Madrid Spain
| | - A. Rivero
- Department of Hematology; Hospital Universitario 12 de Octubre, Universidad Complutense, CNIO; Madrid Spain
| | - J. J. Lahuerta
- Department of Hematology; Hospital Universitario 12 de Octubre, Universidad Complutense, CNIO; Madrid Spain
| | - J. Martinez-Lopez
- Department of Hematology; Hospital Universitario 12 de Octubre, Universidad Complutense, CNIO; Madrid Spain
| |
Collapse
|
25
|
Rivero-Juarez A, Frias M, Martinez-Peinado A, Risalde MA, Rodriguez-Cano D, Camacho A, García-Bocanegra I, Cuenca-Lopez F, Gomez-Villamandos JC, Rivero A. Familial Hepatitis E Outbreak Linked to Wild Boar Meat Consumption. Zoonoses Public Health 2017; 64:561-565. [PMID: 28067990 DOI: 10.1111/zph.12343] [Citation(s) in RCA: 53] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2016] [Indexed: 12/31/2022]
Abstract
An HIV-infected patient was diagnosed with acute hepatitis E infection in our hospital. An epidemiological inquiry was performed to collect demographic, food and animal exposure variables in order to identify the potential route of transmission. The patient reported that his family traditionally hunted wild boar for food. All family members were analysed for hepatitis E virus infection. Additionally, route of transmission by wild boar meat consumption and prevalence of HEV infection among wild boar from the same hunting area were investigated. In all-family members (n = 8), HEV-RNA was amplified. Two wild boar meat slices consumed was analysed, showing the presence of HEV. The virus isolated was consistent with genotype 3, revealing 100% homology between family members and meat. Additionally, we tested nine wild boar hunted in the same hunting area. All of them were RNA-HEV positive, isolating the same HEV genotype 3 viral strain. We demonstrated by phylogenetic analysis zoonotic transmission of HEV by wild boar meat consumption. The prevalence of HEV infection among wild boar found in our study suggests that this species is an important route of transmission to human.
Collapse
Affiliation(s)
- A Rivero-Juarez
- Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba, Cordoba, Spain
| | - M Frias
- Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba, Cordoba, Spain
| | - A Martinez-Peinado
- Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba, Cordoba, Spain
| | - M A Risalde
- Sabio, Instituto de Investigación en Recursos Cinegéticos (CSIC-UCLM-JCCM), Ciudad Real, Spain
| | - D Rodriguez-Cano
- Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba, Cordoba, Spain
| | - A Camacho
- Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba, Cordoba, Spain
| | - I García-Bocanegra
- Animal Health Department, Veterinary Science College, Universidad de Córdoba, Cordoba, Spain
| | - F Cuenca-Lopez
- Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba, Cordoba, Spain
| | - J C Gomez-Villamandos
- Animal Pathology Department, Veterinary Science College, Universidad de Córdoba, Cordoba, Spain
| | - A Rivero
- Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba, Cordoba, Spain
| |
Collapse
|
26
|
Macías J, Real LM, Rivero-Juárez A, Merchante N, Camacho A, Neukam K, Rivero A, Mancebo M, Pineda JA. Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients. HIV Med 2017; 17:766-773. [PMID: 27028546 DOI: 10.1111/hiv.12384] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/12/2016] [Indexed: 12/22/2022]
Abstract
OBJECTIVES There are scant data on the progression of hepatic steatosis (HS) in HIV infection. We therefore evaluated changes in HS over time in HIV-infected patients using the controlled attenuation parameter (CAP). METHODS A prospective cohort of 326 HIV-infected patients was included in this study. All patients underwent a CAP measurement. Changes in steatosis were evaluated by calculating the median (Q1-Q3) difference between baseline and 12-month CAP values. RESULTS The median (Q1-Q3) CAP was 221 (196-252) dB/m at baseline and 224 (198-257) dB/m at the 12-month visit (P = 0.617). Significant steatosis, that is, CAP ≥ 238 dB/m, was observed in 76 individuals (37%) at baseline and in 80 (39%) at the 12-month visit (P = 0.683). The following variables were associated with ΔCAP: plasma HIV RNA [< 50 vs. ≥ 50 HIV-1 RNA copies/mL: median (Q1-Q3) ΔCAP, 4 (-21, 27) vs. -21 (-49, 4) dB/m, respectively; P = 0.024]; body mass index (BMI) [no increase vs. increase: -13 (-40, 4) vs. 14 (-6, 32) dB/m, respectively; P < 0.001]; triglycerides [no increase vs. increase: -1 (-30, 22) vs. 15 (-3, 40) dB/m, respectively; P = 0.001]; fasting plasma glucose [not impaired vs. impaired: -4 (-31, 16) vs. 30 (15, 49) dB/m, respectively; P < 0.001]; and raltegravir [no vs. yes: 5 (-20, 29) vs. -11 (-37.5, 15) dB/m, respectively; P = 0.018]. The only factor independently associated with ΔCAP was BMI [B (standard error): 9.03 (1.9); P < 0.001]. CONCLUSIONS Increases in CAP values over a period of 12 months in HIV-infected patients were strongly associated with elevations in BMI. Other metabolic factors and antiretroviral drugs were not predictors of CAP changes independent of BMI.
Collapse
Affiliation(s)
- J Macías
- Infectious Diseases and Microbiology Unit, Valme University Hospital, Seville, Spain. .,Institute of Biomedicine from Seville (IBiS), Seville, Spain.
| | - L M Real
- Infectious Diseases and Microbiology Unit, Valme University Hospital, Seville, Spain.,Institute of Biomedicine from Seville (IBiS), Seville, Spain
| | - A Rivero-Juárez
- Infectious Diseases Unit, Institute Maimónides of Biomedical Research from Cordoba, Cordoba, Spain
| | - N Merchante
- Infectious Diseases and Microbiology Unit, Valme University Hospital, Seville, Spain.,Institute of Biomedicine from Seville (IBiS), Seville, Spain
| | - A Camacho
- Infectious Diseases Unit, Institute Maimónides of Biomedical Research from Cordoba, Cordoba, Spain
| | - K Neukam
- Infectious Diseases and Microbiology Unit, Valme University Hospital, Seville, Spain.,Institute of Biomedicine from Seville (IBiS), Seville, Spain
| | - A Rivero
- Infectious Diseases Unit, Institute Maimónides of Biomedical Research from Cordoba, Cordoba, Spain
| | - M Mancebo
- Infectious Diseases and Microbiology Unit, Valme University Hospital, Seville, Spain.,Institute of Biomedicine from Seville (IBiS), Seville, Spain
| | - J A Pineda
- Infectious Diseases and Microbiology Unit, Valme University Hospital, Seville, Spain
| |
Collapse
|
27
|
Rivero-Juarez A, Lopez-Cortes LF, Castaño M, Merino D, Marquez M, Mancebo M, Cuenca-Lopez F, Jimenez-Aguilar P, Lopez-Montesinos I, Lopez-Cardenas S, Collado A, Lopez-Ruz MA, Omar M, Tellez F, Perez-Stachowski X, Hernandez-Quero J, Girón-Gonzalez JA, Fernandez-Fuertes E, Rivero A. Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy. Eur J Clin Microbiol Infect Dis 2017; 36:487-494. [PMID: 27787664 PMCID: PMC5309278 DOI: 10.1007/s10096-016-2822-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2016] [Accepted: 10/16/2016] [Indexed: 02/06/2023]
Abstract
In April 2015, the Spanish National Health System (SNHS) developed a national strategic plan for the diagnosis, treatment, and management of hepatitis C virus (HCV). Our aim was to analyze the impact of this on human immunodeficiency virus (HIV)-infected patients included in the HERACLES cohort during the first 6 months of its implementation. The HERACLES cohort (NCT02511496) was set up in March 2015 to evaluate the status and follow-up of chronic HCV infection in patients co-infected with HIV in the south of Spain. In September 2015, the data were analyzed to identify clinical events (death, liver decompensation, and liver fibrosis progression) and rate of treatment implementation in this population. The study population comprised a total of 3474 HIV/HCV co-infected patients. The distribution according to liver fibrosis stage was: 1152 F0-F1 (33.2 %); 513 F2 (14.4 %); 641 F3 (18.2 %); 761 F4 (21.9 %); and 407 whose liver fibrosis was not measured (12.3 %). During follow-up, 248 patients progressed by at least one fibrosis stage [7.1 %; 95 % confidence interval (CI): 6.3-8 %]. Among cirrhotic patients, 52 (6.8 %; 95 % CI: 5.2-8.9 %) developed hepatic decompensation. In the overall population, 50 patients died (1.4 %; 95 % CI: 1.1-1.9 %). Eight hundred and nineteen patients (23.56 %) initiated interferon (IFN)-free treatment during follow-up, of which 47.8 % were cirrhotic. In our study, during 6 months of follow-up, 23.56 % of HIV/HCV co-infected patients included in our cohort received HCV treatment. However, we observed a high incidence of negative short-term outcomes in our population.
Collapse
Affiliation(s)
- A Rivero-Juarez
- Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía de Córdoba, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Avenida Menéndez Pidal s/n, 14004, Córdoba, Spain.
| | - L F Lopez-Cortes
- Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain
| | - M Castaño
- Unidad Clínica de Enfermedades Infecciosas, Hospital Regional Universitario Carlos Haya, Málaga, Spain
| | - D Merino
- Unidad Clínica de Enfermedades Infecciosas, Complejo Hospitalario Universitario de Huelva, Huelva, Spain
| | - M Marquez
- Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Regional Universitario Virgen de la Victoria, Málaga, Spain
| | - M Mancebo
- Unidad Clínica de Enfermedades Infecciosas y Microbiología, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario de Valme, Seville, Spain
| | - F Cuenca-Lopez
- Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía de Córdoba, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Avenida Menéndez Pidal s/n, 14004, Córdoba, Spain
| | - P Jimenez-Aguilar
- Unidad Clínica de Enfermedades Infecciosas, Hospital Universitario Puerto Real, Cádiz, Spain
| | - I Lopez-Montesinos
- Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Seville, Spain
| | - S Lopez-Cardenas
- Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital de Jerez, Jerez, Spain
| | - A Collado
- Unidad Clínica de Enfermedades Infecciosas, Complejo Hospitalario Torrecárdenas, Almería, Spain
| | - M A Lopez-Ruz
- Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen de las Nieves, Granada, Spain
| | - M Omar
- Unidad Clínica de Enfermedades Infecciosas, Complejo Hospitalario de Jaén, Jaén, Spain
| | - F Tellez
- Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital La Línea, AGS Campo de Gibraltad, Cádiz, Spain
| | | | - J Hernandez-Quero
- Unidad Clínica de Enfermedades Infecciosas, Hospital Universitario San Cecilio, Granada, Spain
| | - J A Girón-Gonzalez
- Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Puerta del Mar, Cádiz, Spain
| | | | - A Rivero
- Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía de Córdoba, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Avenida Menéndez Pidal s/n, 14004, Córdoba, Spain.
| |
Collapse
|
28
|
Rivero-Juarez A, Cuenca-Lopez F, Martinez-Peinado A, Camacho A, Real LM, Frias M, Gordon A, Cantisán S, Torre-Cisneros J, Pineda JA, Rivero A. Rural habitat as risk factor for hepatitis E virus seroconversion in HIV-infected patients: A prospective longitudinal study. Zoonoses Public Health 2017; 64:e60-e64. [PMID: 28236361 DOI: 10.1111/zph.12347] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2016] [Indexed: 12/15/2022]
Abstract
Our objective was to determine the incidence and clinical manifestations of acute hepatitis E virus (HEV) in HIV-infected patients. A prospective longitudinal study including HIV-infected HEV-seronegative patients was conducted; HEV seroconversion (to IgG and/or IgM) was the main outcome variable. All patients were tested for HEV antibodies every 3-6 months. For patients who developed HEV seroconversion, a data collection protocol was followed to identify associated clinical manifestations and analytical alterations. A total of 627 patients (89.9%) were followed during a median of 11.96 months (IQR: 8.52-14.52 months) and formed the study population. Forty-one patients developed detectable anti-HEV antibodies (7.2 cases per 100 patients/year). Our study found a high incidence of HEV in HIV-infected patients in southern Spain strongly associated with a rural habitat.
Collapse
Affiliation(s)
- A Rivero-Juarez
- Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía de Córdoba. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain
| | - F Cuenca-Lopez
- Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía de Córdoba. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain
| | - A Martinez-Peinado
- Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía de Córdoba. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain
| | - A Camacho
- Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía de Córdoba. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain
| | - L M Real
- Unidad de Enfermedades Infecciosas y Microbiología Clínica, Hospital Universitario de Valme, Instituto de Biomedicina de Sevilla (IBIS), Seville, Spain
| | - M Frias
- Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía de Córdoba. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain
| | - A Gordon
- Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía de Córdoba. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain
| | - S Cantisán
- Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía de Córdoba. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain
| | - J Torre-Cisneros
- Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía de Córdoba. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain
| | - J A Pineda
- Unidad de Enfermedades Infecciosas y Microbiología Clínica, Hospital Universitario de Valme, Instituto de Biomedicina de Sevilla (IBIS), Seville, Spain
| | - A Rivero
- Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía de Córdoba. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain
| |
Collapse
|
29
|
Núñez-Torres R, Macías J, Rivero-Juarez A, Neukam K, Merino D, Téllez F, Merchante N, Gómez-Mateos J, Rivero A, Pineda JA, Real LM. Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients. HIV Med 2017; 18:546-554. [PMID: 28116842 DOI: 10.1111/hiv.12489] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/18/2016] [Indexed: 01/01/2023]
Abstract
OBJECTIVES Fatty liver disease (FLD) is frequently observed in HIV-infected patients. Obesity and type 2 diabetes mellitus (T2DM) are strongly associated with FLD. Because genetic variants within the fat mass and obesity-associated (FTO) gene have been associated with both pathologies, our aim was to evaluate the association of single nucleotide polymorphisms (SNPs) within the FTO, previously related to obesity or T2DM, with FLD in HIV-infected patients. METHODS FLD was defined as a value of the controlled attenuation parameter (CAP) ≥ 238 dB/m, obtained by transient elastography. Four SNPs within FTO intron 1 (rs11642841, rs8050136, rs9939609 and rs9940128) were genotyped in 421 individuals using a custom Golden Gate protocol. The results were replicated in a validation sample consisting of a further 206 HIV-infected patients. Multivariate logistic regression analyses were conducted in the entire population. RESULTS Three SNPs (rs8050136, rs9939609 and rs9940128) were associated with FLD, with rs9940128 showing the strongest association. This polymorphism also showed an association with FLD in the validation sample. In total, rs9940128 was genotyped in 627 HIV-infected patients, including 267 (42.6%) FLD-diagnosed individuals. The frequency of FLD among rs9940128 AA carriers was 55.7% (63 of 113 individuals) and that in patients without this genotype was 39.7% (204 of 514 individuals) [P = 0.009; adjusted odds ratio 1.88; 95% confidence interval (CI) 1.17-3.01]. CONCLUSIONS Variations within FTO may be predictors of FLD in HIV-infected patients independently of metabolic factors.
Collapse
Affiliation(s)
- R Núñez-Torres
- Unit of Infectious Diseases and Microbiology, Valme University Hospital, Seville, Spain
| | - J Macías
- Unit of Infectious Diseases and Microbiology, Valme University Hospital, Seville, Spain.,Instituto de Biomedicina de Sevilla (IBIS), Seville, Spain
| | - A Rivero-Juarez
- Unit of Infectious Diseases, Reina Sofía University Hospital, Córdoba, Spain.,Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBC), University of Córdoba, Córdoba, Spain
| | - K Neukam
- Unit of Infectious Diseases and Microbiology, Valme University Hospital, Seville, Spain.,Instituto de Biomedicina de Sevilla (IBIS), Seville, Spain
| | - D Merino
- Unit of Infectious Diseases, Huelva University Hospital, Huelva, Spain
| | - F Téllez
- Unit of Infectious Diseases, La Línea de la Concepción Hospital, Cadiz, Spain
| | - N Merchante
- Unit of Infectious Diseases and Microbiology, Valme University Hospital, Seville, Spain.,Instituto de Biomedicina de Sevilla (IBIS), Seville, Spain
| | - J Gómez-Mateos
- Unit of Infectious Diseases and Microbiology, Valme University Hospital, Seville, Spain.,Instituto de Biomedicina de Sevilla (IBIS), Seville, Spain
| | - A Rivero
- Unit of Infectious Diseases, Reina Sofía University Hospital, Córdoba, Spain
| | - J A Pineda
- Unit of Infectious Diseases and Microbiology, Valme University Hospital, Seville, Spain
| | - L M Real
- Unit of Infectious Diseases and Microbiology, Valme University Hospital, Seville, Spain.,Instituto de Biomedicina de Sevilla (IBIS), Seville, Spain
| | | |
Collapse
|
30
|
Frías M, Rodríguez-Cano D, Cuenca-López F, Macías J, Gordon A, Manzanares-Martín B, Pineda JA, Camacho Á, Torre-Cisneros J, Peña J, Rivero-Juárez A, Rivero A. HLA-B18 as risk factor of liver fibrosis progression in HIV/HCV treatment-experienced patients. Pharmacogenomics J 2016; 17:479-480. [DOI: 10.1038/tpj.2016.80] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
31
|
Pigeault R, Garnier R, Rivero A, Gandon S. Evolution of transgenerational immunity in invertebrates. Proc Biol Sci 2016; 283:rspb.2016.1136. [PMID: 27683366 DOI: 10.1098/rspb.2016.1136] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2016] [Accepted: 09/06/2016] [Indexed: 11/12/2022] Open
Abstract
Over a decade ago, the discovery of transgenerational immunity in invertebrates shifted existing paradigms on the lack of sophistication of their immune system. Nonetheless, the prevalence of this trait and the ecological factors driving its evolution in invertebrates remain poorly understood. Here, we develop a theoretical host-parasite model and predict that long lifespan and low dispersal should promote the evolution of transgenerational immunity. We also predict that in species that produce both philopatric and dispersing individuals, it may pay to have a plastic allocation strategy with a higher transgenerational immunity investment in philopatric offspring because they are more likely to encounter locally adapted pathogens. We review all experimental studies published to date, comprising 21 invertebrate species in nine different orders, and we show that, as expected, longevity and dispersal correlate with the transfer of immunity to offspring. The validity of our prediction regarding the plasticity of investment in transgenerational immunity remains to be tested in invertebrates, but also in vertebrate species. We discuss the implications of our work for the study of the evolution of immunity, and we suggest further avenues of research to expand our knowledge of the impact of transgenerational immune protection in host-parasite interactions.
Collapse
Affiliation(s)
- R Pigeault
- MIVEGEC (UMR CNRS 5290), Montpellier, France
| | - R Garnier
- Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ 08544, USA
| | - A Rivero
- MIVEGEC (UMR CNRS 5290), Montpellier, France
| | - S Gandon
- CEFE (UMR CNRS 5175), Montpellier, France
| |
Collapse
|
32
|
Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Palacios R, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S. Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study). J Antimicrob Chemother 2016; 72:246-253. [DOI: 10.1093/jac/dkw379] [Citation(s) in RCA: 52] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2016] [Revised: 08/02/2016] [Accepted: 08/10/2016] [Indexed: 11/13/2022] Open
|
33
|
Guirao-Arrabal E, Santos F, Redel-Montero J, Vaquero JM, Cantisán S, Vidal E, Torre-Giménez Á, Rivero A, Torre-Cisneros J. Risk of tuberculosis after lung transplantation: the value of pretransplant chest computed tomography and the impact of mTOR inhibitors and azathioprine use. Transpl Infect Dis 2016; 18:512-9. [PMID: 27224905 DOI: 10.1111/tid.12555] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2015] [Revised: 01/16/2016] [Accepted: 02/29/2016] [Indexed: 01/24/2023]
Abstract
BACKGROUND It is necessary to determine the incidence and risk factors for tuberculosis (TB), as well as strategies to assess and treat latent tuberculosis infection (LTBI) in lung transplant recipients. METHODS A retrospective cohort study of 398 lung transplant recipients was performed. Episodes of TB were studied and the incidence rate was calculated. Logistic regression analysis was used to analyze specific variables as potential risk factors for TB. RESULTS Median follow-up was 558 days (range 1-6636). Six cases (1.5%) of TB were documented in 398 transplant patients. The incidence density of TB was 406.3 cases/10(5) patient-years (95% confidence interval [CI] 164.7-845), which is higher than in the general population (13.10 cases/10(5) person-years). All cases occurred in the period 1993-2006, when the tuberculin skin test (TST) and treatment of LTBI in positive TST patients were not part of the protocol. Pretransplant computed tomography (CT) showed residual lesions in 50% of patients who developed TB, although the TST was negative and the chest radiograph was inconclusive. Multivariate analysis identified the presence of residual lesions in the pretransplant chest CT (odds ratio [OR] 11.5, 95% CI 1.9-69.1, P = 0.008), use of azathioprine (OR 10.6, 95% CI 1.1-99.1, P = 0.038), and use of everolimus (OR 6.7, 95% CI 1.1-39.8, P = 0.036) as independent risk factors for TB. CONCLUSIONS Residual lesions in the pretransplant chest CTs and the use of azathioprine and mTOR inhibitors are associated with the risk of TB.
Collapse
Affiliation(s)
- E Guirao-Arrabal
- Infectious Diseases Unit, Hospital Universitario Reina Sofía, Córdoba, Spain.,Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Córdoba, Spain
| | - F Santos
- Thoracic Surgery and Lung Transplantation Unit, Hospital Universitario Reina Sofía, Córdoba, Spain
| | - J Redel-Montero
- Thoracic Surgery and Lung Transplantation Unit, Hospital Universitario Reina Sofía, Córdoba, Spain
| | - J M Vaquero
- Thoracic Surgery and Lung Transplantation Unit, Hospital Universitario Reina Sofía, Córdoba, Spain
| | - S Cantisán
- Infectious Diseases Unit, Hospital Universitario Reina Sofía, Córdoba, Spain.,Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Córdoba, Spain
| | - E Vidal
- Infectious Diseases Unit, Hospital Universitario Reina Sofía, Córdoba, Spain.,Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Córdoba, Spain
| | - Á Torre-Giménez
- Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Córdoba, Spain
| | - A Rivero
- Infectious Diseases Unit, Hospital Universitario Reina Sofía, Córdoba, Spain.,Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Córdoba, Spain
| | - J Torre-Cisneros
- Infectious Diseases Unit, Hospital Universitario Reina Sofía, Córdoba, Spain.,Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Córdoba, Spain
| |
Collapse
|
34
|
Rivero-Juarez A, Gonzalez R, Frias M, Manzanares-Martín B, Rodriguez-Cano D, Perez-Camacho I, Gordon A, Cuenca F, Camacho A, Pineda JA, Peña J, Rivero A. KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy. Pharmacogenomics J 2016; 17:360-365. [PMID: 26975229 DOI: 10.1038/tpj.2016.19] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/27/2015] [Revised: 01/22/2016] [Accepted: 01/27/2016] [Indexed: 12/28/2022]
Abstract
Our aim was to evaluate the killer cell immunoglobulin-like receptors (KIRs) as a marker for the development of thrombocytopenia secondary to Peg-interferon (IFN) therapy in a cohort of human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infected patients. Patients were naive to HCV treatment, receiving a first course of Peg-IFN/Ribavirin combination therapy. Total platelet count (cells ml-1) was determined at each visit, determining platelet decline from baseline to weeks 1, 2, 4, 8 and 12 after starting therapy. The end point of the study was development of thrombocytopenia, defined as a platelet count of <1 50 000 cells ml-1. Fifty-eight HIV/HCV co-infected patients were included in the study, of whom 20 (34.4%) developed thrombocytopenia. The absence of KIR2DS2 was associated with higher and faster rate of thrombocytopenia (54.2% vs 22.5%; P=0.012; 6.6 vs 10.3 weeks; P=0.008). The absence of KIR2DS2 was associated with a greater decline in platelet count and development of thrombocytopenia during Peg-IFN treatment in HIV/HCV co-infected patients.
Collapse
Affiliation(s)
- A Rivero-Juarez
- Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba, Córdoba, Spain
| | - R Gonzalez
- Immunology Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain
| | - M Frias
- Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba, Córdoba, Spain
| | - B Manzanares-Martín
- Immunology Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain
| | - D Rodriguez-Cano
- Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba, Córdoba, Spain
| | - I Perez-Camacho
- Service de Medicina Tropical, Hospital de Poniente, El Ejido, Almería, Spain
| | - A Gordon
- Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba, Córdoba, Spain
| | - F Cuenca
- Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba, Córdoba, Spain
| | - A Camacho
- Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba, Córdoba, Spain
| | - J A Pineda
- Infectious Diseases and Clinical Microbiology Unit, Hospital Universitario de Valme, Seville, Spain
| | - J Peña
- Cellular Biology, Physiology and Immunology Department, Universidad de Córdoba, Córdoba, Spain
| | - A Rivero
- Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba, Córdoba, Spain
| |
Collapse
|
35
|
Abstract
Transgenerational effects of infection have a huge potential to influence the prevalence and intensity of infections in vectors and, by extension, disease epidemiology. These transgenerational effects may increase the fitness of offspring through the transfer of protective immune factors. Alternatively, however, infected mothers may transfer the costs of infection to their offspring. Although transgenerational immune protection has been described in a dozen invertebrate species, we still lack a complete picture of the incidence and importance of transgenerational effects of infection in most invertebrate groups. The existence of transgenerational infection effects in mosquito vectors is of particular interest because of their potential for influencing parasite prevalence and intensity and, by extension, disease transmission. Here we present what we believe to be the first study on transgenerational infection effects in a mosquito vector infected with malaria parasites. The aim of this experiment was to quantify both the benefits and the costs of having an infected mother. We find no evidence of transgenerational protection in response to a Plasmodium infection. Having an infected mother does, however, entail considerable fecundity costs for the offspring: fecundity loss is three times higher in infected offspring issued from infected mothers than in infected offspring issued from uninfected mothers. We discuss the implications of our results and we call for more studies looking at transgenerational effects of infection in disease vectors.
Collapse
Affiliation(s)
- R Pigeault
- MIVEGEC, UMR CNRS 5290, Montpellier, France
| | - J Vézilier
- MIVEGEC, UMR CNRS 5290, Montpellier, France CEFE, UMR CNRS 5175, Montpellier, France
| | - A Nicot
- MIVEGEC, UMR CNRS 5290, Montpellier, France CEFE, UMR CNRS 5175, Montpellier, France
| | - S Gandon
- CEFE, UMR CNRS 5175, Montpellier, France
| | - A Rivero
- MIVEGEC, UMR CNRS 5290, Montpellier, France
| |
Collapse
|
36
|
Abstract
Invertebrate hosts often bring forward their reproductive effort in response to a parasitic infection. This is widely interpreted as a host-driven response aimed at compensating for the expected losses in future fitness as a result of parasitism. Here we report that mosquitoes bring forward their oviposition schedule when they are infected with Plasmodium, a parasite known to severely curtail mosquito fecundity. This response could aim at compensating for a negative time-dependent effect of the parasite on mosquito fitness, as infected mosquitoes seem to display a strong and progressive decrease in the quality of the eggs they lay. In addition, we show that this shift in oviposition date is dependent on mosquito strain: a comparison of several isogenic mosquitoes strains, one insecticide-susceptible and two insecticide-resistant ones, reveals that only the former shift their oviposition strategy when infected. This pattern suggests the existence of a costly host-driven response to parasitism, as insecticide-resistant mosquitoes have been shown to be in generally poorer condition.
Collapse
Affiliation(s)
- J Vézilier
- MIVEGEC (CNRS UMR 5290), Montpellier, France
| | - A Nicot
- CEFE (UMR CNRS 5175), Montpellier, France
| | - S Gandon
- CEFE (UMR CNRS 5175), Montpellier, France
| | - A Rivero
- MIVEGEC (CNRS UMR 5290), Montpellier, France
| |
Collapse
|
37
|
Rivero-Juarez A, Gutierrez-Valencia A, Castaño M, Merino D, Neukam K, Ríos-Villegas MJ, Lopez-Ruz MA, Jiménez-Aguilar P, Marquez M, Collado A, Gomez-Vidal A, Hernandez-Quero J, Tellez F, Fernandez-Fuertes E, Rivero A, López-Cortés LF. Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain. Eur J Clin Microbiol Infect Dis 2015; 34:2247-55. [PMID: 26342330 PMCID: PMC4607719 DOI: 10.1007/s10096-015-2476-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2015] [Accepted: 08/20/2015] [Indexed: 02/08/2023]
Abstract
The implementation of hepatitis C (HCV) direct-acting antiviral drugs is prioritized in several populations in which its application provides the most immediate and impactful benefit. In this scenario, a precise knowledge of the situation of human immunodeficiency virus (HIV)/HCV chronic co-infection is required to adequately address this disease. This cross-sectional study was performed in 21 hospitals in Andalusia (Spain). The study population consisted of HIV-infected patients with an active HCV chronic infection who were not receiving HCV treatment at the time of inclusion. A total of 13,506 HIV-infected patients were included in the study. Of them, 2561 (18.9 %) presented chronic HCV infection. The majority of the patients included were on highly active antiretroviral therapy (HAART; 96.2 %), showed plasma levels with an undetectable HIV viral load (92.5 %), and had a good immunological status (median CD4+ cell count of 486 cells/mL). The HCV genotype distribution was as follows: 58.1 % were genotype 1, 1.1 % were genotype 2, 16.1 % were genotype 3, and 22.1 % were genotype 4 (2.6 % were missing data). In total, 24.8 % of the patients showed liver fibrosis stage F0-F1, 27.9 % showed stage F2, 16.7 % showed stage F3, and 21 % showed stage F4 (9.6 % were missing data). With regards to previous HCV treatment experiences, 68.05 % of the patients were naïve and 31.95 % had failed to respond to a previous treatment. The burden of HCV/HIV co-infected patients in our population was reported as one in five HIV-infected patients requiring HCV treatment. The implementation of extra resources to face this important health challenge is mandatory.
Collapse
Affiliation(s)
- A Rivero-Juarez
- Unidad Clínica de Enfermedades Infecciosas, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Hospital Universitario Reina Sofía, Avda. Menendez Pidal s/n, 14004, Cordoba, Spain.
| | - A Gutierrez-Valencia
- Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain
| | - M Castaño
- Unidad Clínica de Enfermedades Infecciosas, Hospital Regional Universitario Carlos Haya, Málaga, Spain
| | - D Merino
- Unidad Clínica de Enfermedades Infecciosas, Complejo Hospitalario Universitario de Huelva, Huelva, Spain
| | - K Neukam
- Unidad Clínica de Enfermedades Infecciosas y Microbiología, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario de Valme, Seville, Spain
| | - M J Ríos-Villegas
- Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Seville, Spain
| | - M A Lopez-Ruz
- Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen de las Nieves, Granada, Spain
| | - P Jiménez-Aguilar
- Unidad Clínica de Enfermedades Infecciosas, Hospital Universitario Puerto Real, Cádiz, Spain
| | - M Marquez
- Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Regional Universitario Virgen de la Victoria, Málaga, Spain
| | - A Collado
- Unidad Clínica de Enfermedades Infecciosas, Complejo Hospitalario Torrecárdenas, Almería, Spain
| | - A Gomez-Vidal
- Unidad Clínica de Enfermedades Infecciosas, Complejo Hospitalario de Jaén, Jaén, Spain
| | - J Hernandez-Quero
- Unidad Clínica de Enfermedades Infecciosas, Hospital Universitario San Cecilio, Granada, Spain
| | - F Tellez
- Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital La Línea, AGS Campo de Gibraltad, Cádiz, Spain
| | - E Fernandez-Fuertes
- Unidad Clínica de Enfermedades Infecciosas, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Hospital Universitario Reina Sofía, Avda. Menendez Pidal s/n, 14004, Cordoba, Spain
- Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain
- Unidad Clínica de Enfermedades Infecciosas, Hospital Regional Universitario Carlos Haya, Málaga, Spain
- Unidad Clínica de Enfermedades Infecciosas, Complejo Hospitalario Universitario de Huelva, Huelva, Spain
- Unidad Clínica de Enfermedades Infecciosas y Microbiología, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario de Valme, Seville, Spain
- Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Seville, Spain
- Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen de las Nieves, Granada, Spain
- Unidad Clínica de Enfermedades Infecciosas, Hospital Universitario Puerto Real, Cádiz, Spain
- Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Regional Universitario Virgen de la Victoria, Málaga, Spain
- Unidad Clínica de Enfermedades Infecciosas, Complejo Hospitalario Torrecárdenas, Almería, Spain
- Unidad Clínica de Enfermedades Infecciosas, Complejo Hospitalario de Jaén, Jaén, Spain
- Unidad Clínica de Enfermedades Infecciosas, Hospital Universitario San Cecilio, Granada, Spain
- Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital La Línea, AGS Campo de Gibraltad, Cádiz, Spain
- Unidad de Medicina Tropical, Hospital de Poniente, Almería, Spain
| | - A Rivero
- Unidad Clínica de Enfermedades Infecciosas, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Hospital Universitario Reina Sofía, Avda. Menendez Pidal s/n, 14004, Cordoba, Spain.
| | - L F López-Cortés
- Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain
| |
Collapse
|
38
|
Garcia Recuero I, Romance A, Rivero A, Redondo M, Hinojosa P, Pascual B. Monobloc and Le-Fort III distraction in syndromic craniosynostosis using a computer designed RED II halo type distractor. Int J Oral Maxillofac Surg 2015. [DOI: 10.1016/j.ijom.2015.08.556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
39
|
Rivero-Juarez A, Caruz A, Real LM, Martinez-Dueñas L, Marquez FJ, Frias M, Recio E, Gordon A, Pineda JA, Rivero A, Camacho A. Longitudinal evaluation of hepatitis C viral persistence in HIV-infected patients with spontaneous hepatitis C clearance. Eur J Clin Microbiol Infect Dis 2015; 34:2171-5. [PMID: 26254560 DOI: 10.1007/s10096-015-2463-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2015] [Accepted: 07/21/2015] [Indexed: 01/30/2023]
Abstract
Hepatitis C virus (HCV) viral persistence in patients with spontaneous viral clearance is controversial. Several studies have shown HCV-RNA in peripheral blood mononuclear cells (PBMCs) and/or liver tissue among patients who have cleared the virus spontaneously, suggesting that viral persistence is a common situation that could involve the entire population studied. Thus, our aim was to evaluate HCV-RNA persistence in PBMCs and hepatocytes in subjects infected with the human immunodeficiency virus (HIV). A total of 1508 patients were prospectively followed and tested for anti-HCV antibodies and HCV-RNA to identify the patients who achieved spontaneous viral clearance. In all of the patients, the persistence of HCV-RNA in PBMCs was evaluated longitudinally during 2 years of follow-up. Fifty-nine patients fulfilled the inclusion/exclusion criteria and were included in the study. HCV-RNA was not detected in the PBMCs at baseline [59 PBMCs samples tested; 0 %; 95 % confidence interval (CI): 0-3.3 %] or during the follow-up (147 PBMCs samples tested; 0 %; 95 % CI: 0-2.02 %). Our study shows that HCV viral persistence is not a frequent occurrence in HIV-infected patients who have spontaneously resolved an HCV infection. Thus, the lack of serum HCV-RNA should continue to be addressed as the standard of healing.
Collapse
Affiliation(s)
- A Rivero-Juarez
- Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Avd. Menéndez Pidal s/n, 14004, Córdoba, Spain
| | - A Caruz
- Immunogenetics Unit, Department of Experimental Biology, University of Jaen, Jaen, Spain
| | - L M Real
- Infectious Diseases Unit, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario de Valme, Sevilla, Spain
| | - L Martinez-Dueñas
- Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Avd. Menéndez Pidal s/n, 14004, Córdoba, Spain
| | - F J Marquez
- Immunogenetics Unit, Department of Experimental Biology, University of Jaen, Jaen, Spain
| | - M Frias
- Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Avd. Menéndez Pidal s/n, 14004, Córdoba, Spain
| | - E Recio
- Infectious Diseases Unit, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario de Valme, Sevilla, Spain
| | - A Gordon
- Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Avd. Menéndez Pidal s/n, 14004, Córdoba, Spain
| | - J A Pineda
- Infectious Diseases Unit, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario de Valme, Sevilla, Spain
| | - A Rivero
- Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Avd. Menéndez Pidal s/n, 14004, Córdoba, Spain.
| | - A Camacho
- Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Avd. Menéndez Pidal s/n, 14004, Córdoba, Spain
| |
Collapse
|
40
|
Monje-Agudo P, Castro-Iglesias A, Rivero-Juárez A, Martínez-Marcos F, Ortega-González E, Real LM, Pernas B, Merchante N, Cid P, Macías J, Merino MD, Rivero A, Mena A, Neukam K, Pineda JA. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin. Eur J Clin Microbiol Infect Dis 2015; 34:1929-36. [PMID: 26155784 DOI: 10.1007/s10096-015-2434-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2015] [Accepted: 06/22/2015] [Indexed: 12/18/2022]
Abstract
It is commonly accepted that human immunodeficiency (HIV) coinfection negatively impacts on the rates of sustained virological response (SVR) to therapy with pegylated interferon plus ribavirin (PR). However, this hypothesis is derived from comparing different studies. The aim of this study was to determine the impact of HIV coinfection on SVR to PR in one single population. In a multicentric, prospective study conducted between 2000 and 2013, all previously naïve hepatitis C virus (HCV)-infected patients who started PR in five Spanish hospitals were analyzed. SVR was evaluated 24 weeks after the scheduled end of therapy. Of the 1046 patients included in this study, 413 (39%) were coinfected with HIV. Three hundred and forty-one (54%) HCV-monoinfected versus 174 (42%) HIV/HCV-coinfected patients achieved SVR (p < 0.001). The corresponding figures for undetectable HCV RNA at treatment week 4 were 86/181 (47%) versus 59/197 (30%), p < 0.001. SVR was observed in 149 (69%) HCV genotype 2/3-monoinfected subjects versus 91 (68%) HIV/HCV genotype 2/3-coinfected subjects (p = 0.785). In the HCV genotype 1/4-infected population, 188 (46%) monoinfected patients versus 82 (30%) with HIV coinfection (p < 0.001) achieved SVR. In this subgroup, absence of HIV coinfection was independently associated with higher SVR [adjusted odds ratio (95% confidence interval): 2.127 (1.135-3.988); p = 0.019] in a multivariate analysis adjusted for age, sex, baseline HCV RNA load, IL28B genotype, fibrosis stage, and type of pegylated interferon. HIV coinfection impacts on the rates of SVR to PR only in HCV genotype 1/4-infected patients, while it has no effect on SVR in the HCV genotype 2/3-infected subpopulation.
Collapse
Affiliation(s)
- P Monje-Agudo
- Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Avda de Bellavista s/n, 41014, Sevilla, Spain
| | - A Castro-Iglesias
- Clinical Virology Group, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidad de A Coruña, 15006, A Coruña, Spain
| | - A Rivero-Juárez
- Unit of Infectious Diseases, Hospital Universitario Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Avda Menéndez Pidal s/n, 14004, Córdoba, Spain
| | - F Martínez-Marcos
- Unit of Infectious Diseases, Complejo Hospitalario de Huelva, Ronda Exterior Norte s/n, 21005, Huelva, Spain
| | - E Ortega-González
- Unit of Infectious Diseases, Consorcio Hospital General Universitario de Valencia, Av. Tres Cruces s/n, 46014, Valencia, Spain
| | - L M Real
- Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Avda de Bellavista s/n, 41014, Sevilla, Spain
| | - B Pernas
- Clinical Virology Group, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidad de A Coruña, 15006, A Coruña, Spain
| | - N Merchante
- Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Avda de Bellavista s/n, 41014, Sevilla, Spain
| | - P Cid
- Clinical Virology Group, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidad de A Coruña, 15006, A Coruña, Spain
| | - J Macías
- Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Avda de Bellavista s/n, 41014, Sevilla, Spain
| | - M D Merino
- Unit of Infectious Diseases, Complejo Hospitalario de Huelva, Ronda Exterior Norte s/n, 21005, Huelva, Spain
| | - A Rivero
- Unit of Infectious Diseases, Hospital Universitario Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Avda Menéndez Pidal s/n, 14004, Córdoba, Spain
| | - A Mena
- Clinical Virology Group, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidad de A Coruña, 15006, A Coruña, Spain
| | - K Neukam
- Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Avda de Bellavista s/n, 41014, Sevilla, Spain.
| | - J A Pineda
- Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Avda de Bellavista s/n, 41014, Sevilla, Spain
| |
Collapse
|
41
|
Mira JA, Neukam K, López-Cortés LF, Rivero-Juárez A, Téllez F, Girón-González JA, de los Santos-Gil I, Ojeda-Burgos G, Merino D, Ríos-Villegas MJ, Collado A, Torres-Cornejo A, Macías J, Rivero A, Pérez-Pérez M, Pineda JA. Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia. Eur J Clin Microbiol Infect Dis 2015; 34:1879-84. [PMID: 26115631 DOI: 10.1007/s10096-015-2426-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2015] [Accepted: 06/05/2015] [Indexed: 01/21/2023]
Abstract
The aim of this study was to assess the efficacy of and the risk of major bleeding during pegylated interferon (peg-IFN)/ribavirin (RBV) treatment among human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients according to the pretreatment platelet count. Two hundred and seventy-four HCV/HIV-coinfected, previously naïve individuals with compensated cirrhosis enrolled in one Spanish prospective cohort who received peg-IFN/RBV were included in this study. The frequency of severe bleeding and sustained virological response (SVR) rate were compared between patients with a pretreatment platelet count ≤70,000/mm(3) and >70,000/mm(3), respectively. Sixty-one (22 %) patients had a baseline platelet count ≤70,000/mm(3). The median (Q1-Q3) pretreatment platelet count was 58,000 (49,000-65,000) cells/mm(3) in the platelet ≤70,000 group and 129,000 (102,500-166,000) cells/mm(3) in the platelet >70,000 group (p < 0.0001). Seventeen (28 %) subjects of the platelet ≤70,000 group and 71 (33 %) patients of the platelet >70,000 group achieved SVR (p = 0.4). Only 2 (3.2 %) patients in the platelet ≤70,000 group developed a severe hemorrhagic event, specifically esophageal variceal bleeding. The efficacy of therapy with peg-IFN/RBV in HIV/HCV-coinfected patients with low pretreatment platelet counts is comparable to that found in the overall subset of subjects with compensated cirrhosis. The frequency of severe hemorrhagic events related with this therapy is low in this population.
Collapse
Affiliation(s)
- J A Mira
- Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Avenida de Bellavista S/N, 41014, Sevilla, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Gracia-Ahufinger I, Ferrando-Martínez S, Montejo M, Muñoz-Villanueva M, Cantisán S, Rivero A, Solana R, Leal M, Torre-Cisneros J. Pre-transplant thymic function is associated with the risk of cytomegalovirus disease after solid organ transplantation. Clin Microbiol Infect 2015; 21:511.e1-7. [DOI: 10.1016/j.cmi.2014.12.020] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2014] [Revised: 12/20/2014] [Accepted: 12/24/2014] [Indexed: 11/28/2022]
|
43
|
Agostini P, Rivero A, Parra Martin JA, Soares-de-Almeida L. Pedunculated polypoid melanoma. A case report of a rare spindle-cell variant of melanoma. Dermatol Online J 2015; 21:13030/qt1dk8750f. [PMID: 25933079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2015] [Accepted: 04/15/2015] [Indexed: 06/04/2023] Open
Abstract
We report an 89-year-old man who presented with a slowly growing pigmented pedunculated tumor. The nodule was diagnosed as a spindle cell pedunculated malignant melanoma (PMM), a rare variant of spindle-cell malignant melanoma. The clinical presentation of this tumor and its histological and immunohistological features are discussed.
Collapse
|
44
|
Cantisán S, Rodelo-Haad C, Páez-Vega A, Nieto A, Vaquero JM, Poyato A, Montejo M, Fariñas MC, Rivero A, Solana R, Martín-Malo A, Torre-Cisneros J. Factors related to the development of CMV-specific CD8+ T cell response in CMV-seropositive solid organ transplant candidates. Am J Transplant 2015; 15:715-22. [PMID: 25648131 DOI: 10.1111/ajt.13012] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2014] [Revised: 09/10/2014] [Accepted: 09/11/2014] [Indexed: 01/25/2023]
Abstract
This cross-sectional study analyzes factors associated with the development of CMV-specific CD8+ response, measured by IFNg production after cytomegalovirus (CMV) peptide stimulation, in CMV-seropositive solid organ transplantation candidates. A total of 114 candidates were enrolled, of whom 22.8% (26/114) were nonreactive (IFNγ < 0.2 IU/mL). Multivariate logistic regression analysis showed that age, HLA alleles and organ to be transplanted were associated with developing CMV-specific CD8+ immunity (reactive; IFNγ ≥ 0.2 IU/mL). The probability of being reactive was higher in candidates over 50 than in those under 50 (OR 6.33, 95%CI 1.93-20.74). Candidates with HLA-A1 and/or HLA-A2 alleles had a higher probability of being reactive than those with non-HLA-A1/non-HLA-A2 alleles (OR 10.97, 95%CI 3.36-35.83). Renal candidates had a higher probability of being reactive than lung (adjusted OR 8.85, 95%CI 2.24-34.92) and liver candidates (OR 4.87, 95%CI 1.12-21.19). The AUC of this model was 0.84 (p < 0.001). Positive and negative predictive values were 84.8% and 76.9%, respectively. In renal candidates longer dialysis was associated with an increased frequency of reactive individuals (p = 0.040). Therefore, although the assessment of CMV-specific CD8+ response is recommended in all R+ candidates, it is essential in those with a lower probability of being reactive, such as non-renal candidates, candidates under 50 or those with non-HLA-A1/non-HLA-A2 alleles.
Collapse
Affiliation(s)
- S Cantisán
- Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)/Reina Sofia University Hospital/University of Cordoba, Cordoba, Spain; Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015), Instituto de Salud Carlos III, Madrid, Spain
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Manzaneque A, Sotoca JM, Rivero A, Camos A, Matas J, Adán A, Codina C. DI-014 Off label use and economic impact of biologic therapy in non-infectious uveitis. Eur J Hosp Pharm 2015. [DOI: 10.1136/ejhpharm-2015-000639.192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
46
|
Santos J, Palacios R, López M, Gálvez MC, Lozano F, de la Torre J, Ríos MJ, López-Cortés LF, Rivero A, Torres-Tortosa M. Simplicity and Efficacy of a Once-Daily Antiretroviral Regimen with Didanosine, Lamivudine, and Efavirenz in Naïve Patients: The VESD Study. HIV Clinical Trials 2015; 6:320-8. [PMID: 16566083 DOI: 10.1310/1xae-bb0w-qn5r-ajgj] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
PURPOSE Our aim was to analyze the efficacy and safety of didanosine-lamivudine-efavirenz in a cohort of HIV patients starting antiretroviral therapy between January and September 2003. METHOD We undertook a prospective, open-label, observational, multicenter study. RESULTS 163 patients were enrolled. Over a 48-week period, plasma HIV RNA levels declined sharply, with a median decrease at the end of the observation time of >4.62 log copies/mL. The proportion of patients achieving a plasma HIV RNA level below 50 copies/mL was 62.9% (intention-to-treat analysis) at the end of the study period. The mean CD4 cell count increased steadily over time by 199 cells/microL. Antiviral efficacy was similar in patients with a baseline HIV RNA level above or below 100,000 copies/mL. Overall, 57 (34.1%) patients interrupted therapy; 9 due to lack of treatment response, 18 due to adverse side-effects, and 30 patients lost to follow-up or who withdrew their consent. Adherence was very high (90%-95%) and quality of life was good or very good in 69%. CONCLUSION The once-daily combination of didanosine-lamivudine-efavirenz resulted in sustained viral suppression and was well-accepted by patients under real-life conditions, even immunosuppressed patients and those with a high viral load. Associated adverse events and virological failures were few.
Collapse
Affiliation(s)
- J Santos
- Infectious Diseases Unit, Hospital Virgen de la Victoria, Málaga, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Herrero R, Real LM, Rivero-Juárez A, Pineda JA, Camacho Á, Macías J, Laplana M, Konieczny P, Márquez FJ, Souto JC, Soria JM, Saulle I, Lo Caputo S, Biasin M, Rivero A, Fibla J, Caruz A. Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection. Genes Immun 2015; 16:134-41. [PMID: 25569262 DOI: 10.1038/gene.2014.71] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2014] [Revised: 11/10/2014] [Accepted: 11/12/2014] [Indexed: 11/09/2022]
Abstract
HIV-1 induces activation of complement through the classical and lectin pathways. However, the virus incorporates several membrane-bound or soluble regulators of complement activation (RCA) that inactivate complement. HIV-1 can also use the complement receptors (CRs) for complement-mediated antibody-dependent enhancement of infection (Ć-ADE). We hypothesize that hypofunctional polymorphisms in RCA or CRs may protect from HIV-1 infection. For this purpose, 139 SNPs located in 19 RCA and CRs genes were genotyped in a population of 201 Spanish HIV-1-exposed seronegative individuals (HESN) and 250 HIV-1-infected patients. Two SNPs were associated with infection susceptibility, rs1567190 in CR2 (odds ratio (OR) = 2.27, P = 1 × 10(-4)) and rs2842704 in C4BPA (OR = 2.11, P = 2 × 10(-4)). To replicate this finding, we analyzed a cohort of Italian, sexually HESN individuals. Although not significant (P = 0.25, OR = 1.57), similar genotypic proportions were obtained for the CR2 marker rs1567190. The results of the two association analyses were combined through a random effect meta-analysis, with a significant P-value of 2.6 x 10(-5) (OR = 2.07). Furthermore, we found that the protective CR2 genotype is correlated with lower levels CR2 mRNA as well as differences in the ratio of the long and short CR2 isoforms.
Collapse
Affiliation(s)
- R Herrero
- Immunogenetics Unit, Department of Experimental Biology, University of Jaen, Jaen, Spain
| | - L M Real
- Infectious Diseases and Microbiology Clinical Unit. Valme Hospital, Seville, Spain
| | - A Rivero-Juárez
- Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/Reina Sofia University Hospital, Cordoba, Spain
| | - J A Pineda
- Infectious Diseases and Microbiology Clinical Unit. Valme Hospital, Seville, Spain
| | - Á Camacho
- Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/Reina Sofia University Hospital, Cordoba, Spain
| | - J Macías
- Infectious Diseases and Microbiology Clinical Unit. Valme Hospital, Seville, Spain
| | - M Laplana
- Human Genetics Unit, Department of Basic Medical Sciences, University of Lleida IRBLleida, Lleida, Catalonia, Spain
| | - P Konieczny
- Immunogenetics Unit, Department of Experimental Biology, University of Jaen, Jaen, Spain
| | - F J Márquez
- Immunogenetics Unit, Department of Experimental Biology, University of Jaen, Jaen, Spain
| | - J C Souto
- Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), Hospital de la Santa Creu i de Sant Pau, Barcelone, Spain
| | - J M Soria
- Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), Hospital de la Santa Creu i de Sant Pau, Barcelone, Spain
| | - I Saulle
- Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
| | | | - M Biasin
- Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
| | - A Rivero
- Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/Reina Sofia University Hospital, Cordoba, Spain
| | - J Fibla
- Human Genetics Unit, Department of Basic Medical Sciences, University of Lleida IRBLleida, Lleida, Catalonia, Spain
| | - A Caruz
- Immunogenetics Unit, Department of Experimental Biology, University of Jaen, Jaen, Spain
| |
Collapse
|
48
|
Palacios R, Rivero A, Santos I, Ríos MJ, Castaño M, del Arco A, Santos J. Rapid Improvement in Fasting Lipids and Hepatic Toxicity After Switching From Didanosine/Lamivudine to Tenofovir/Emtricitabine in Patients With Toxicity Attributable to Didanosine. HIV Clinical Trials 2015; 11:118-20. [DOI: 10.1310/hct1102-118] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
49
|
Agostini P, Rivero A, Parra Martin JA, Soares-de-Almeida L. Pedunculated polypoid melanoma. A case report of a rare spindle-cell variant of melanoma. Dermatol Online J 2015. [DOI: 10.5070/d3214026276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
|
50
|
Gonzalez-Padilla M, Torre-Cisneros J, Rivera-Espinar F, Pontes-Moreno A, Lopez-Cerero L, Pascual A, Natera C, Rodriguez M, Salcedo I, Rodriguez-Lopez F, Rivero A, Rodriguez-Bano J. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2014; 70:905-13. [DOI: 10.1093/jac/dku432] [Citation(s) in RCA: 78] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
|